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The Miniature Schnauzer has been anecdotally reported to have a hereditary 
predisposition to the development of pancreatitis. The aims of this study were to 
establish a true breed predisposition for the disease and to investigate a potential genetic 
etiology. 
The first part of this study investigated breed predisposition for the development 
of pancreatitis. Miniature Schnauzers were found to have an odds ratio of 1.23 (P = 
0.0240) for having an increased cPLI (as measured by an in-house ELISA or by Spec 
cPL®) serum concentration compared to the population as a whole. 
The second part of this study investigated the SPINK1 gene in Miniature 
Schnauzers with and without evidence of pancreatitis. Three variants were found in the 
gene and Miniature Schnauzers that were homozygous for the variants had an odds ratio 
of 25 (P = 0.0067) for having clinical and biochemical evidence of pancreatitis 
compared to healthy individuals. 
The third part of the study examined the entire canine genome using SNP 
scanning to investigate other genes or regions that may be associated with pancreatitis in 
the Miniature Schnauzer. The analysis revealed only a small region on chromosome 2 
that was associated with the phenotype of pancreatitis. The SPINK1 gene is also located 
in this region.  
The final part of the study attempted to determine if one of the variants found in 
the second part of the study altered the final cDNA transcript. mRNA was extracted 
 iii 
 
from the pancreas of Miniature Schnauzers known to have the variants and their cDNA 
was transcribed. It was found that this variant did not lead to exon skipping or truncation 
of the final protein transcript. 
In conclusion, this study demonstrated an increased prevalence of the phenotype 
of pancreatitis in the Miniature Schnauzer and was able to statistically associate this 
phenotype with variants in the SPINK1 gene. 
Further investigation into the mechanisms that may alter the structure, function, 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
Physiology of the exocrine pancreas  
Pancreatic enzymes can be divided into three major groups based on their 
function: enzymes that digest proteins, enzymes that digest carbohydrates, and those that 
digest lipids or fats.1 The main enzymes responsible for protein digestion are trypsin, 
chymotrypsin, carboxypeptidase, and elastase, among others.1 Trypsin and chymotrypsin 
break proteins into small peptides while, carboxypeptidase cleaves off individual amino 
acids.1 Carbohydrate digestion is accomplished principally by pancreatic amylase.1 
Amylase hydrolyzes starches, glycogen, and other carbohydrates primarily into 
disaccharides.1 Lipids are digested by pancreatic lipase, phospholipase, and cholesterol 
esterase.1  
Pancreatic secretion is under the influence of three main stimuli. The first is via 
acetylcholine, which is a neurotransmitter released from both the parasympathetic vagus 
and also from cholinergic nerves.1 Acetylcholine is responsible for the cephalic and 
gastric phases of pancreatic secretion.1 However, it only allows for moderate release of 
zymogen granules into the acinar ducts.1 The other two stimuli are secretin and 
cholecystokinin.1-5 The peptide hormone secretin is released in response to acidic chyme 
in the duodenum by duodenal enteroendocrine cells.1,2,5 Secretin causes the pancreas to 
secrete large amounts of sodium bicarbonate that, in turn, buffer the intraluminal pH.1,2 
This subsequent pH change helps to create an environment that is conducive to 
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pancreatic enzyme activation.1 It should be noted that the intestinal mucosa is also able 
to secrete bicarbonate.5 Cholecystokinin is activated by the presence of food in the 
duodenum and its release stimulates the pancreas to release large amounts of both 
zymogen granules and active enzymes.2,4,5 Simultaneously, the intestinal mucosa 
releases enterokinase in response to the detection of chyme.5,6 Enterokinase cleaves the 
activation peptide off trypinsogen, leading to active trypsin.5 Trypsin, in turn, can 
activate more trypsinogen and also the remainder of the other zymogens.1,2,4,5,7   
Since several active enzymes can damage pancreatic acinar cells, many of these 
enzymes are secreted from the pancreas in an inactive pro-form known as zymogens.5 
Trypsinogen and chymotrypsinogen are examples of such zymogens. Pro-elastase and 
prophospholipase are other examples.1 However, other enzymes such as amylase and 
lipase are secreted in their active form.4 In order to protect the pancreas further, the pro-
enzymes and zymogens, upon being synthesized in the rough endoplasmic reticulum, are 
transported to the Golgi apparatus to undergo selective glycosylation.2,4,5 Lysosomal 
hydrolases are intracellular enzymes that could potentially lead to premature activation 
of zymogens and are packed separately from zymogen. The separation is based on the 6-
phosphoryl mannose receptor that zymogens lack.2 Since zymogens do not have a 
mannose tag, they are transported separately for their eventual release into the ductal 
lumen by exocytosis.8  As an additional safeguard from auto-activation, pancreatic 
secretory trypsin inhibitor (PSTI) is co-synthesized, co-transported, and co-stored with 




Pathophysiology of pancreatitis 
Retention and premature activation of trypsinogen within acinar cells has been 
suggested to be the initiating event leading to pancreatitis using electron microscopy as.9 
A secretory block occurs on the apical membrane of acinar cells, which does not allow 
the release of zymogen granules from the cell. This sets the stage for the inappropriate 
co-localization of zymogen granules and lysosomes.9 During this fusion of zymogen 
granules and lysosomes, trypsinogen is thought to be activated to trypsin primarily by 
cathepsin B, although other mechanisms or mediators may also be involved.9,10 
Additionally, pH in the co-localized giant vacuoles is also an important factor leading to 
trypsinogen activation, as a low pH can lead to auto-activation of trypsinogen.11 
Although premature activation of trypsinogen within the acinar cell is the earliest 
abnormality seen, the initial intracellular trigger is unknown. There is evidence that the 
concentration of free calcium within the acinar cell may play an important role as an 
initial event.12,13 Calcium plays a role in the activation of trypsinogen to trypsin as pure 
inhibition of calcium signaling stops the activation of trypsinogen.14,15 Indeed, sustained 
increased acinar calcium concentrations are also toxic to cells. Many risk factors for 
pancreatitis including ductal hypertension, hypoxia, hyperlipidemia, and others have 
been shown to increase acinar calcium concentrations, many through an impairment of 
the acinar Ca2+-ATPase mechanism.12,13 In some instances, PSTI may stop further 
premature activation of trypsinogen and pancreatitis does not ensue.3,9,16,17 However, if 
the system and other protective mechanisms are overwhelmed, pancreatitis may develop.  
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The pathophysiology of pancreatitis is complex and is due not only to activated 
digestive enzymes causing local damage but also to systemic spread of enzymes and 
activation of the inflammatory and coagulation cascades, which may cause systemic 
inflammatory response syndrome (SIRS), disseminated intravascular coagulation (DIC), 
acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome 
(MODS) in severe cases.9,16 Inflammation of the pancreas leads to vasodilation and 
ultimately granulocyte migration.9 Neutrophil migration is mediated by chemokines, 
primarily IL-8, but can also be driven by the presence of trypsin and elastase.18,19 
Additionally, neutrophils may cause a shift from apoptotic pancreatic cells to necrosis. 
Apoptosis, unlike necrosis, does not elicit and inflammatory response.20 Increased 
vascular permeability due to inflammation may also cause hypercoagulability, which can 
be a major cause of morbidity and mortality in humans.9,21 
The pancreas is very sensitive to ischemia and poor perfusion. Vasoconstriction 
of the pancreatic capillaries has been shown to worsen pancreatitis experimentally and is 
also considered to be a risk factor for the disease.22-26 Other substances such as 
bradykinin, C5a, substance P, TNF-α, and the activation of NF-kβ are also significant 
contributors to the severity and pathophysiology of pancreatitis and are currently being 
investigated.9 The role of these substances has been reviewed extensively elsewhere.9,16 
Genetic mutations and variants also play a role in the pathophysiology of pancreatitis 
(see the following section for a comprehensive review of these mechanisms). 
The pathophysiology of pancreatitis is complex and multifactorial and current 
investigations are also looking into the role of pancreatic duct cells. There is increasing 
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evidence that alterations in calcium signaling in pancreatic ductal cells play a major role 
in cellular damage during pancreatitis.6 The acinar cells secrete a viscous, proteinaceous, 
acidic, and Cl--rich fluid, while pancreatic ductal cells secrete a bicarbonate-rich and low 
viscosity fluid that acts to neutralize protons secreted by acinar cells and keeps 
zymogens in their inactive form until they reach the duodenal lumen.27,28 Ductal cell 
secretion, as mentioned previously, is mediated in response to a meal due to cell 
membrane surface recognition of the two main agonists, secretin and acetylcholine. 
These agonists bind to G proteins via membrane receptors, which results in activation of 
adenylyl cyclase and eventual release of Ca2+ from intracellular stores.6 The basolateral 
surface of pancreatic ductal cells contains Na+/HCO3- cotransporters that transport both 
molecules into the cell in response to increased intracellular Ca2+.29 Additionally, CO2 is 
probably passively diffused through the same membrane and is converted to HCO3- via 
carbonic anhydrase.30 The luminal surface of ductal cells contains Cl-/HCO3- exchangers 
and the cystic fibrosis transmembrane conductance regulator protein (CFTR) 
channels.31,32 These allow for the transport of the intracellular HCO3- into the ductal 
lumen. As mentioned previously, CFTR mutations may impair this mechanism. Such 
mutations, as well as the presence of bile acids, ethanol, or other substances will also 
inhibit ductal secretion.33,34 These substances will induce intracellular bicarbonate 
secretion and calcium release, which is sustained.6 This chronic calcium release will 
inhibit the efficacy of physiologic secretagogues, leading to cell necrosis.6 Cellular death 
will lead to an inflammatory reaction that may further lead to premature trypsin 
activation closing a vicious cycle. In addition, Pallagi et al. demonstrated that 
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prematurely activated trypsin reduces pancreatic ductal bicarbonate secretion via PAR-2 
inhibition of the apical exchanger and CFTR channel, which also decreases luminal pH 
leading to further activation of zymogens.35 It is likely that further discoveries of 
defective calcium signaling and pancreatic ductal cell malfunction will contribute to the 
understanding of the pathogenesis of pancreatitis. 
 
Hereditary pancreatitis in humans 
Despite being recognized as a potentially genetic disease in 1952, prior to the 
1990’s, gallstones and alcoholism were considered the primary cause of pancreatitis.36-38 
Indeed the first report of an association between alcohol and pancreatic disease was 
described in a 1788 case report of a thirty-four year old gentleman "who was accustomed 
to free living and strong corporeal exertions in the pursuit of country amusements".37 At 
necropsy, his pancreas was found to have a number of pancreatic calculi present.37 
However, as time progressed it was increasingly recognized that children without cystic 
fibrosis (another recognized cause of pancreatitis) were being diagnosed with 
pancreatitis at an early age without the aforementioned risk factors. Additionally, cases 
of familial pancreatitis were being reported. In 1996 during the birth of modern genetics, 
using the candidate gene approach, the first genetic mutations that were associated with 
pancreatitis were reported and not only helped elucidate mechanisms behind the 
development of acute and chronic pancreatitis but also established the possible 
progression from acute to chronic pancreatitis.37,39  
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Whitcomb et al. discovered a gain-in-function mutation in the gene (PRSS1), 
encoding for cationic trypsinogen that was associated with pancreatitis in families with 
pancreatitis.39 The variant discovered was a substitution mutation that replaced an 
arginine with a histidine at residue 117.39,40 One of the mechanisms of protecting the 
pancreas from autodigestion is the ability of trypsin to auto-digest itself by breaking 
peptide chains at arginine or lysine residues.36 X-ray crystallography demonstrated that 
the R117 residue site was critical for self-autolysis and, as such, a substitution would not 
allow for trypsin-like hydrolysis of the chain connecting the two domains required for 
trypsin activity, thus creating a “super-trypsin” that is resistant to auto-degradation.39 
Since this initial discovery, approximately 20 gain-of-function mutations have been 
discovered in the gene and have been identified in 80% of families with hereditary 
pancreatitis.40 These discoveries have been pivotal in the understanding of ductal and 
acinar cell pathophysiology during both acute and chronic pancreatitis. Studies of these 
mutations have demonstrated that acute pancreatitis can lead to chronic pancreatitis and 
that trypsin is the key molecule responsible for the initiation of pancreatitis. 
Additionally, many of these mutations are near calcium binding sites on the protein and, 
as a result, the critical role of calcium as the key regulator of trypsin has also been 
further explained.39-42 
The SPINK1 (serum protease inhibitor, Kazal type 1) gene encodes for pancreatic 
secretory trypsin inhibitor (PSTI), which is an acute phase protein that is present in 
acinar cells, especially during times of inflammation. PSTI represents another protective 
mechanism against premature trypsin activation, by inhibiting prematurely activated 
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trypsin molecules and thus preventing further autoactivation.36,40 Witt and later Pfutzer 
et al. demonstrated an association with the N34S mutation in children and adults with 
idiopathic pancreatitis.43,44 These and other studies demonstrated that while the 
homozygous variant was closely associated with the phenotype, an increased prevalence 
of the N34S variant (and others) and a high percentage of heterozygotes within 
pancreatitis cohorts raised some speculation as to SPINK1’s role as a causative 
mutation.36,40,43 However, a meta-analysis of 24 studies of the importance of the N34S 
variant in chronic pancreatitis revealed strong evidence that mutations of SPINK1 are 
more closely tied to idiopathic pancreatitis (OR: 14.97) and chronic pancreatitis (OR: 
11.00) than even alcohol use (OR: 4.98).21,45 Other studies have documented other 
variants including the Ans34Ser and a splice variant IVS3+2T>C, which are common.36 
The role of SPINK1 is causative in homozygous individuals. However, heterozygocity is 
only associated with pancreatitis when other variants in other susceptibility genes 
(PRSS1, CFTR, etc.) are present. This is extremely important in the increased 
recognition of families with a variable number of multiple germline pathogenic gene 
variants that affect trypsin regulation.21,36,40,46 
In humans, variants of the cystic fibrosis transmembrane conductance protein, 
which is coded by the gene CFTR, have also been associated with recurrent acute or 
chronic pancreatitis.47-49 CFTR is an anion channel that allows for the movement of 
chloride and bicarbonate across the apical membrane of the pancreatic duct cell (but they 
also occur in lungs, sweat glands, and other organs), which causes an increase of pH and 
flushing of pancreatic zymogens into the duodenal lumen.40 There are over 2,000 known 
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mutations of this gene and, in humans mutations are classically associated with cystic 
fibrosis.36,48 Cystic fibrosis is a syndrome that is characterized by the presence of thick 
and abnormal secretions in the lungs. However, patients may also present with advanced 
chronic pancreatitis and malabsorption, depending on the mutations present in the 
gene.36,47,48 The main defect in this gene alters the protein, which acts as a protein 
channel that regulates the movement of chloride ions in an and out of cells.47,48 In 
patients with genotypes that cause pancreatitis, the mutations result in defective 
bicarbonate secretion from pancreatic ductal cells, which is also responsible for flushing 
trypsin out of the pancreatic duct. Variants that cause dysfunction of this protein allow 
for retention of zymogens within the duct in which they can become activated and lead 
to autodigestion of the pancreas.47 In humans, mutations of the CFTR gene are classified 
based on the severity of protein modification and the presence of a severe pathogenic 
variant (CFTRSEV) on each allele leads to the clinical condition of cystic fibrosis. 
However, the presence of only one allele (CFTRSEV) and a bicarbonate-defective variant 
(CFTRBD) on the other allele, or also the presence of two bicarbonate-defective variants 
(CFTRBD/CFTRBD) leads to pancreatitis.36 Additionally, in humans, hereditary 
pancreatitis is strongly associated with the N34S mutation of the SPINK1 gene. 
However, few people with mutations actually develop the clinical syndrome.48 Studies 
have now shown that the presence of the N34S mutation and a co-mutation with the 
CFTR variant p.R75Q is significantly (OR: 3.4) associated with chronic pancreatitis.48 
Thus, CFTR variants on their own may cause pancreatitis as well as potentially acting as 
a modifier gene for SPINK1 mutations or vice versa. Indeed, the combination of a 
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mutation that increases trypsinogen activation (CFTR/PRSS1) along with a mutation that 
alters the ability of the pancreas to protect itself (SPINK1) appears to the common 
pattern responsible for potentially 1/3 of recurrent acute and chronic pancreatitis cases in 
humans.21,36,46 This is currently being investigated in the NAPS2 (North American 
Pancreatitis Studies) clinical study, which aims to evaluate a large cohort of patients 
with pancreatitis using genome-wide association studies and next generation sequencing 
to help elucidate the complex relationship between the three main genes implicated in 
hereditary pancreatitis (i.e., PRSS1, CFTR, and SPINK1).46 
Several other genes have been evaluated in human patients with pancreatitis and 
are now largely considered disease modifiers as they do not cause pancreatitis on their 
own but play a role in families with complex and multiple germline gene 
variants.21,36,40,46 For example, the gene CASR encodes for the calcium sensing receptor 
that is located on the cell membrane of numerous cells.50 Its job is to sense calcium 
concentrations outside of the cell and to initiate a variety of cell mechanisms to respond 
to the calcium level.21,40,50 Variants of the CASR gene are commonly associated with 
pathogenic variants of CFTR and suggest a misinterpretation of the calcium level and 
premature opening of CFTR channels during times of high ductal calcium 
concentrations, which can cause premature activation of trypsin.21,40 
Chymotrypsin C, which is encoded by CTRC, is a minor pancreatic enzyme that 
is co-synthesized with trypsinogen.40,51 It has been speculated that besides it’s digestive 
properties, chymotrypsin B is also able to degrade trypsin when activated, thus 
belonging to the body's defense against pancreatic autodigestion.40 Variants found within 
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this gene are not thought to be causative of pancreatitis alone, but they are often 
associated other mutations in the CFTR or SPINK1 gene and are part of the pathogenetic 
process in families with multiple gene variants that cumulatively  put them at risk for 
pancreatitis.40,51,52 
Claudin-2, which is a tight junction protein expressed in the proximal pancreatic 
duct, forms cation-selective ion and water channels between endothelial cells and is 
thought to be responsible for allowing transport of water and sodium into the pancreatic 
duct to match chloride and bicarbonate secretion through the CFTR protein.3,53,54 A risk 
allele T of the gene CLDN2 is associated with nearly half of all men with alcoholic 
pancreatitis.3,21,53,54  Furthermore, immunohistochemical studies of surgical specimens 
show increased levels of this protein within acinar cells and an altered localization, but 
the definitive pathophysiology leading to pancreatitis has yet to be determined.21  
In conclusion, multiple genes have been implicated in humans with pancreatitis. 
Some genes are believed to be causative, while many others may be silent unless 
combined with other risk variants from other genes or environmental factors such as 
alcohol abuse. Indeed, human pancreatitis is emerging to be an exciting disease to study 
both complex genetic traits and epistasis genetics.21 
  
Pancreatitis in the dog  
Pancreatitis in the dog has been divided into two categories, acute and chronic, 
which can only be differentiated based on histopathology.4,5,7,55,56 In contrast to humans, 
there is no consensus for the definitions of acute versus chronic pancreatitis in the 
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dog.4,5,7,17,56 To complicate matters further, temporal relationships appear to exist in the 
clinical presentation of patients with “acute or chronic pancreatitis” and various other 
terms are commonly assigned to these manifestations.56 Thus, risk factors and etiologies 
overlap in the literature and for the purpose of this study they are not differentiated 
unless noted. 
Acute pancreatitis usually considered to be a temporal and reversible disease, 
which is often associated with edema and neutrophilic infiltration, and in severe cases 
can also be associated with pancreatic necrosis.4,5,7,17,56 In contrast, chronic pancreatitis 
is characterized by permanent changes, such as fibrosis and parenchymal atrophy and is 
mostly associated with lympho-plasmacytic inflammation, yet patients with chronic 
pancreatitis may show an “acute” clinical manifestation.17,56,57 Generally, acute and 
chronic pancreatitis cannot be differentiated clinically and many cases may indeed 
represent “acute-on-chronic” disease. This is supported by a recent report where 58/63 
dogs had concurrent acute and chronic changes on histopathology, while only 5 dogs had 
purely acute disease.3,55,58 
The etiologies and risk factors of acute pancreatitis in the dog are not very well 
understood.5,7 In the majority of dogs diagnosed with acute pancreatitis, an underlying 
condition cannot be identified and the cause is considered idiopathic.5,7 Signalment has 
been implicated as a risk factor for pancreatitis.8,59,60 In two older studies, dogs that were 
6 years or older were identified to be at increased risk.8,59 Older studies did not identify a 
sex predilection.8,59 Another study found that neutering increased the odds of pancreatitis 
in dogs, similarly to the findings of a previous study.8,60 
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 Breed predisposition is generally anecdotal but a few reports can be found in the 
literature.8,59,60 There are only a few papers that discuss breed in association with 
histologically confirmed pancreatitis.3,17,61 Hess et al. only identified the Yorkshire 
Terrier (OR: 41.8; 95%CI: 1.0 - 1,731) in her study. Notwithstanding the confidence 
intervals found, the control group was significantly younger, more likely intact and of a 
larger breed, and were more likely underweight.8 In 1993 Cook et al. reported a 
retrospective study of 101 dogs and made the observation that “Terrier” breeds were at 
an increased risk. However, it should be noted that in that study, only 37 of the dogs had 
histopathological evidence and the other cases were diagnosed with pancreatitis using 
less than ideal criteria. Additionally, the results of histopathology were not discussed.  
However, dogs were placed in groups based on the AKC groups and it should be 
mentioned that the AKC grouping does not necessarily place genetically related dogs 
together but primarily assigns dogs based on their intended use and not their genetic 
relatedness.59 A very old paper mentions 10 dogs with chronic pancreatitis and their 
respective breed. However, there were no controls mentioned in this paper, nor does the 
author try to associate any specific breed with this condition.62 A recent paper evaluated 
200 dogs at post-mortem in order to assess the prevalence of chronic pancreatitis in the 
UK.55 This study identified Cavalier King Charles Spaniels, Collies, and Boxers as 
having an increased risk for chronic pancreatitis, however in 24.5% of the cases, the 
pancreas was too autolyzed to interpret, especially in large breed dogs, potentially 
biasing the results.55 A unique syndrome in Europe has been recognized in English 
Cocker Spaniels.  These dogs often have keratoconjunctivitis sicca or protein-losing 
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nephropathy and concurrent chronic pancreatitis. The histopathology in these dogs is 
reported to be unique and is characterized by perilobular and periductal progressive 
fibrosis and is characterized on immunohistochemistry by T-cell dominated lymphocyte 
infiltration with plasma cells that stain positive for IgG4.55,56 A recent study of chronic 
pancreatitis found that pure bred dogs were 3.35 times more likely to have chronic 
pancreatitis and also were more likely to belong to an AKC toy and non-sporting breed 
(OR: 2.83).57 These dogs were also 10.2 times more likely to have clinical as opposed to 
subclinical chronic pancreatitis.57 Lem et al. published a report examining dietary factors 
and pancreatitis, and found that Miniature Schnauzers, Yorkshire Terriers, and 
“Terriers” in general had an increased risk for developing pancreatitis. In these cases, 
pancreatitis was diagnosed based on a variety of clinical criteria.60 Interestingly, despite 
a strong clinical suspicion that Miniature Schnauzers may be predisposed to pancreatitis, 
this has not yet been substantiated in the literature. Bostrom et al. reported on a group of 
dogs with chronic pancreatitis that when compared to the general necropsy population 
were more likely to be neutered (OR: 4.64) and female (OR: 2.17).57 
 Dietary indiscretion has long been implicated as a risk factor for pancreatitis in 
dogs.5,7,17,60 In  a recent retrospective study showed that the ingestion of unusual food 
items and a history of eating table scraps increased the odds for pancreatitis, although no 
specific food was implicated.60 This same study also demonstrated that overweight dogs 
were predisposed to pancreatitis although this may have been related to more frequent 
dietary indiscretion in this group of dogs.60 It has been shown that high fat diets given 
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experimentally can induce pancreatic enzyme secretion, but histopathology was not 
performed to determine whether the pancreatitis had ensued.63  
 Metabolic and endocrine diseases are also implicated as a cause of 
pancreatitis.5,7,17  Conditions such as hyperadrenocorticism and hypothyroidism have 
been associated with an increased risk, but a cause and effect relationship has not been 
definitively proven.8,17,59,64 Diabetes mellitus is also associated with pancreatitis but may 
be more of consequence of chronic pancreatitis as the current literature suggests that as 
many as 30% of dogs with diabetes mellitus may have chronic pancreatitis.56 Dogs with 
chronic pancreatitis in one study were 13.5 times more likely to have concurrent 
endocrine diseases than the general necropsy population.57 Of the 61 dogs with chronic 
pancreatitis, 12 had diabetes mellitus, 4 had hypothyroidism, and 1 each had hyper- and 
hypoadrenocorticism.57 Increased serum triglyceride concentrations >900 mg/dl, at least 
in the Miniature Schnauzer, has also been shown to be associated with increased Spec 
cPL concentrations and several of the endocrine diseases mentioned are associated with 
secondary hyperlipidemia, which may be responsible for the increased risk for 
pancreatitis.17,65 
 Drugs are thought to play a role in acute pancreatitis in the dog, but conclusive 
evidence is lacking for many implicated drugs. Drugs that have been implicated in the 
etiology of pancreatitis include calcium, L-asparaginase, potassium bromide, 
phenobarbital, and antimonial drugs, however evidence for each is mostly 
anecdotal.17,66,67 It has recently been reported that dogs being treated with potassium 
bromide, phenobarbital, or both drugs in combination, had an increased risk for having 
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an increased serum cPLI concentration.67 Also, a case report implicated N-methyl-
glutamine as a cause of acute pancreatitis, however a subsequent abstract found no 
association of the administration of this drug with increased Spec-cPL concentrations in 
a larger population of dogs.68 Experimentally, a number of procedures involving the 
administration of caerulein, carbamylcholine, and scorpion venom induced pancreatitis 
in dogs.7 A study looking into naturally infected dogs with Leishmania that were treated 
with meglumine antimonite did not, however, reveal an increased serum Spec cPL 
concentration or clinical signs compatible with pancreatitis.68 
 Infections only rarely are considered the cause of pancreatitis in the dog. 
However, isolated reports of Babesia canis, Klebsiella pneumonia, and Pseudomonas 
aeruginosa pancreatic infections can be found.5,69,70 In a recent retrospective study of 
dogs, primarily in Texas, infected with Heterobilharzia americana that had undergone 
necropsy, 35% had trematode eggs in the pancreas associated with inflammation.71 This 
finding may implicate this organism as a potentially under-reported cause of pancreatitis 
but further studies are warranted.  Finally, a recent study from Greece demonstrated a 
serum Spec cPL concentration suggestive of pancreatitis in 20% of dogs with naturally 
infected Ehrlichia canis, however clinical signs were minimal in affected dogs.72 
 Hypocalcemia has been implicated as a risk factor for pancreatitis, but occurs 
uncommonly in acute pancreatitis.73 Approximately 40% of dogs with chronic 
pancreatitis (diagnosed by histopathology) have a low serum ionized calcium.57 
However, increasing evidence indicates that hypocalcemia is common in critically ill 
dogs and may not be specific to pancreatitis. Rather, hypocalcemia in critically ill 
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patients is considered to have a multi-factorial pathophysiology that includes 
derangement of parathyroid hormone and magnesium, changes in chelation or protein 
bound calcium, acid-base imbalances, and third-space loss, among others.73 
 Also, hypoperfusion, ischemia, trauma, and mechanical duct obstruction can all 
cause pancreatitis in the dog.5,17 There is debate regarding whether handling at surgery 
can cause pancreatitis or whether the isolated cases reported are caused by poor 
perfusion of the pancreas during anesthesia. However, it is of note that pancreatitis was 
not found to be a complication in a published report involving laparoscopic pancreatic 
biopsy.74 
 Finally, genetics are a likely risk factor for canine pancreatitis and are the topic 
of this thesis. A study evaluating the cationic trypsinogen gene in Miniature Schnauzers 
with clinical findings consistent with pancreatitis did not reveal any mutations or 
variants.75 Since the Miniature Schnauzer breed has frequently been associated with 
pancreatitis, the objective of this study was to evaluate if the breed is at risk and also 
what gene(s) may be associated with the phenotype of pancreatitis seen in these dogs. 
 The clinical presentation of pancreatitis can vary considerably in dogs.  Dogs 
may be essentially asymptomatic, have mild clinical signs, or may develop life-
threatening DIC and shock.76 Others may also develop icterus from extra-hepatic bile 
duct obstruction secondary to pancreatitis. There are no clinical findings that are 
pathognomonic for pancreatitis in the dog.76 Clinical signs have been reported in dogs 
with acute pancreatitis, which may include anorexia (91%), vomiting (90%), weakness 
(79%), polydipsia and polyuria (50%), and diarrhea (33%).8,59,77 Dogs with chronic 
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pancreatitis had similar clinical signs, including vomiting (88%), hyporexia (98%), 
lethargy (93%), diarrhea (49%), fever (24%), and abdominal pain (35%).57 Physical 
examination findings in dogs with fatal severe acute pancreatitis included dehydration 
(97%), abdominal pain (58%), fever (32%), and icterus (26%).77  
Serum lipase and amylase activities were the original serum markers used for the 
diagnosis of pancreatitis and are considered useful for the diagnosis of pancreatitis in 
humans.78-80 However, in dogs the reported sensitivity for lipase and amylase activities 
are 41-69% and 32-73%, respectively, while the specificities are closer to 50% for 
each.7,17,78-83 Lipase originates from many cell types and organs, including the pancreas, 
liver, stomach, and others, and is thus not specific for exocrine pancreatic 
disease.3,16,56,78-80,84 Indeed, serum lipase activity can be increased in dogs with 
gastroenteritis, liver disease, renal failure, and various other conditions.3,16,78,79,85,86  
Furthermore, lipase activity can be increased after the administration of dexamethasone. 
Therefore, the use of lipase activity is no longer recommended for the diagnosis of 
pancreatitis in the dog.7,16,56,79 
The serum cTLI (canine trypsin-like immunoreactivity) assay was developed and 
validated for the diagnosis of exocrine pancreatic insufficiency and is considered the 
gold standard for the diagnosis of this disease.7,16,17,79,80,84,87,88  Serum cTLI 
concentration is pancreas-specific and during pancreatitis serum cTLI concentration 
increases markedly. However, it also falls quite rapidly, thus limiting the clinical 
usefulness of this marker for the diagnosis of pancreatitis.  The reported sensitivity of 
serum cTLI concentration is 36-47% and this parameter is also not considered to be 
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specific for pancreatitis, thus it is generally not recommended for the diagnosis of 
pancreatitis in dogs.5,16,17,79,80,84,85 
 Canine pancreatic lipase immunoreactivity (cPLI) measures the concentration of 
pancreatic lipase, as opposed to total lipase activity.80,91-93 The original assay for the 
measurement of cPLI was an in-house ELISA, but has now been replaced with the 
commercially available assay, Spec cPL.94 Information on the original assay has been 
extensively reviewed elsewhere.80 The Spec cPL differs from the original assay for the 
measurement of cPLI as the Spec cPL assay uses a monoclonal antibody as opposed to a 
polyclonal antibody used in the original assay.80,84 The assays show good correlation, but 
the reference intervals are different.16 A serum Spec cPL concentration of >400 µg/L is 
considered diagnostic of pancreatic inflammation.17,79,80,84 The in-house SNAP cPL 
exhibits good correlation with the Spec cPL, however all positive results should be 
confirmed by the measurement of Spec cPL in serum as an “abnormal” result of the 
SNAP cPL may indicate a serum concentration in the diagnostic range or also the gray 
or inconclusive range.17,76,80,84 Multiple studies, including a large multi-institutional 
study, have evaluated the Spec cPL for sensitivity and specificity using blinded clinical 
diagnosis by a panel of internists.58,79,95-97 The sensitivity of Spec cPL in this study was 
reported to range between 63.6 and 71% with a specificity ranging between 86 and 
97.5% using 400 µg/L as the diagnostic cut-off value.16,58,79,95,97 These studies have been 
reviewed extensively elsewhere.80 Serum Spec cPL concentrations have been reported to 
be quite stable for days at room temperature, weeks at 4oC, and years at -20oC.17,57,80,98 
The half-life of the assay is approximately 2 hours and thus increased concentrations can 
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be cleared in <24 hours if no further leakage occurs.99 Despite higher numbers that are 
clinically correlated with severity in some cases, there is no current evidence to suggest 
that the higher the serum cPLI concentration, the more severe the disease.76,80 Indeed a 
recent study demonstrated that the Spec cPL concentration must change by ~ 452.6% to 
be considered significantly different. Unlike other GI function tests fasting is not 
essential for the performance of this assay.100 Studies have demonstrated that the use of 
steroids or the presence of chronic kidney disease do not affect results.98,101 However, a 
recent study demonstrated an increased Spec cPL in dogs with hyperadrenocorticism (as 
diagnosed by clinical signs and ACTH stimulation test) compared to healthy dogs, 491.1 
µg/L vs. 74.2 µg/L), which may indicate a high rate of subclinical pancreatitis in dogs 
with hyperadrenocorticism.102 Haworth et al. looked at the diagnostic accuracy of the 
SNAP cPL and Spec cPL in dogs presenting for acute abdomen.103 This study reported 
an agreement between a positive SNAP cPL and a Spec cPL > 400 µg/L and a “clinical 
diagnosis” to be associated with  κ = 0.33 and κ = 0.43, respectively, concluding that 
these assays may be associated with a false positive diagnosis of pancreatitis in dogs 
with abdominal disease.103 However, no histopathology was obtained from dogs from 
either study to rule out any evidence of pancreatitis.102,103 In a study evaluating Spec cPL 
and serum total lipase activity measured with the 1,2-o-dilauryl-rac-glycero-3-glutaric 
acid-(6'-methylresorufin) ester (DGGR) substrate and abdominal ultrasonography, there 
was poor agreement of either assay with abdominal ultrasound.104 Other diagnostic tests 
have been evaluated for the diagnosis of pancreatitis but are not currently recommend 
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due the decreased sensitivity and specificity and/or limited clinical 
availability.17,84,85,105,106 
Abdominal radiography is commonly used in clinical patients for evaluation of 
acute vomiting and abdominal pain, however it is associated with a poor sensitivity 
(24%) and specificity for pancreatitis.77 Classically, decreased serosal detail in the 
cranial right abdomen and displacement of other organs in the region have been 
associated with pancreatitis.76 The true value of abdominal radiography is probably to 
rule out other causes of acute abdomen when evaluating a dog with possible pancreatitis.  
Ultrasonography is currently considered the imaging modality of choice for the 
diagnosis of pancreatitis in the dog. There is however considerable variation in the 
diagnostic sensitivity and specificity based on the skill and experience of the operator 
and the quality of the equipment. The specificity is thought to be high, however the 
highest sensitivity that has been reported is 68% for severe disease.77 In a recent study of 
dogs undergoing abdominal ultrasound for suspicion of pancreatitis, some dogs 
diagnosed with pancreatitis by ultrasonography actually had no evidence of pancreatitis 
on histopathology.74 Indeed, the overall agreement between histopathology and 
ultrasound diagnosis was only 23.1% in this study.74 Generally, ultrasound is thought of 
as supportive evidence with other findings on physical examination, history, and the 
measurement of cPLI concentration for making the clinical diagnosis of 
pancreatitis.16,17,84 
Computed tomography (CT) is the imaging modality of choice for diagnosing 
pancreatitis in human patients but has been poorly evaluated in dogs at this point and 
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further studies are indicated.107 Other studies looking at endoscopic ultrasound and 
retrograde cholangio-pancreatography have been evaluated but are not generally 
available.108-110 In an experimental model of pancreatitis, quantitative contrast-enhanced 
ultrasonography (CEUS) was successfully used to differentiate pancreatitis from normal 
pancreas.111 
Histopathology is considered the gold standard for the diagnosis of pancreatitis. 
However, it has recently been questioned whether it should be considered the standard 
for “clinically significant” pancreatitis.57,61,97,112 Additionally, exclusion of pancreatitis 
may be difficult as studies have shown that lesions may be highly localized and missed 
with routine biopsy.61 Thus, multiple sections must be taken if feasible. Finally, 
pancreatic biopsy is considered invasive and costly and is not routinely performed.  
Further studies are needed to determine whether there is correlation with specific 
histopathology and clinical signs or severity. A recent study did however associate 
higher histological scores for pancreatic and peripancreatic fat necrosis in cases of 
clinical chronic pancreatitis as opposed to asymptomatic cases.57 A histological grading 
scheme has been developed for assessing pancreatitis in dogs.16,112 
The therapy for canine pancreatitis varies according to clinical severity but 
generally centers around fluid therapy, pain control, anti-emetic and -nausea therapy, 
and nutritional support.3-5,7,16,17,56,76 Fluid therapy is essential in severe cases because of 
an increased vascular permeability and progressive reduction of capillaries as a result of 
acinar injury.16  There are no clinical studies evaluating different fluid types in dogs with 
pancreatitis though one clinical study demonstrated that crystalloids may be insufficient 
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and experimental work suggests that dextrans or hypertonic saline may be of 
benefit.16,113-115 Analgesic support is an essential component of the management of dogs 
with pancreatitis.4,5,7,16,17,56,76 Frequently, opioids are considered first line therapy 
tailored to the severity of disease. Anti-nausea drugs are commonly employed for the 
treatment of canine pancreatitis and include maropitant, ondansetron, dolasetron, and 
metoclopramide. There are no clinical studies evaluating the efficacy of these drugs in 
pancreatitis.  
Traditionally, dogs treated for pancreatitis have often been fasted based on the 
assumption that decreased food in the duodenum would “rest” the pancreas. The 
majority of human medical and experimental evidence and one small study in dog 
suggest that enteral nutrition is preferred over parenteral for acute pancreatitis.116 Dogs 
are often fed low fat diets during and post recovery. though studies have demonstrated 
that there is no measurable difference in pancreatic secretion regardless of the fat content 
of food.16 There is evidence that Miniature Schnauzers who are prone to 
hypertriglyceridemia many benefit from a long-term low fat diet and may decrease the 
risk of recurrent pancreatitis.117 The treatment for pancreatitis dogs has been reviewed 








CHAPTER II  
ASSOCIATION BETWEEN BREED AND INCREASED SERUM SPEC CPL 
CONCENTRATIONS IN DOGS 
 
Introduction 
 Breed predilection for pancreatitis is largely anecdotal in the literature. Very few 
papers exist that associate breed with histopathologically confirmed pancreatitis due to 
the invasiveness of the procedure.17 In an early study, Hess et. al identified only the 
Yorkshire Terrier as having a breed predisposition however the control group was 
significantly different in age and sex.8 Cook et. al reported a retrospective study of 101 
dogs and noted  that “terrier” type breeds were at an increased risk, although many cases 
were diagnosed with less than ideal criteria.59 A paper from the UK evaluated chronic 
pancreatitis and identified Cavalier King Charles Spaniels, Collies, and Boxers as being 
at an increased risk.55 Finally a recent epidemiological study that evaluated risk factors 
for pancreatitis identified Miniature Schnauzers and Yorkshire Terriers as being 
predisposed.60 There has been no study to date that examines breed association for 
pancreatitis in a large population of dogs.  
 In humans, pancreatitis was originally thought to be caused by either alcoholism 
or gallstones, however children and families were diagnosed with pancreatitis that did 
not have these predisposing factors.36,37,40 Subsequent studies were able to identify 
genetic mutations in the PRSS1 (cationic trypsinogen), SPINK1 (pancreatic secretory 
trypsin inhibitor), CFTR (cystic fibrosis transmembrane conductance protein), and others 
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that have proven to be causative.21,39-41,43,44,49,118-122 In dogs, there appears to be a breed-
related tendency and it is likely that a gene or genes are involved in the pathogenesis of 
pancreatitis in some breeds. Little work has been done to search for candidate genes in 
dogs. However, previous studies did not yield any abnormalities in the cationic 
trypsinogen, anionic trypsinogen, or lipoprotein lipase gene in Miniature Schnauzers 
with pancreatitis.17,75  
Due to the difficulties in diagnosing pancreatitis, sensitive and specific markers 
for the diagnosis of pancreatitis have been developed.79,89,90,94 The original in-house 
cPLI was replaced with the commercially available Spec cPL assay. This assay has a 
reported sensitivity of 63.6 – 71.0% and a specificity of 86.0 – 97.5% at a diagnostic cut-
off of 400 µg/L.58,80,96,97 Thus, this diagnostic marker may serve as an alternative and 
non-invasive diagnostic test for the purpose of larger epidemiological studies.  
The aim of this study was to investigate breed associations with an increased 
Spec cPL concentration within a population of dogs being tested for suspicion of 
pancreatitis. We hypothesized that breeds with a statistically increased odds ratio for an 
increased Spec cPL may be breeds that are genetically predisposed to the development 
of pancreatitis and further investigation into genetic etiologies in these breeds may be 
warranted. 
 
Materials and methods  
  The database at the Gastrointestinal Laboratory at Texas A&M University was 
reviewed from October 30, 2006 to October 30, 2009 for submissions for the 
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measurement of pancreatic lipase immunoreactivity concentrations by Spec cPL.a Data 
was collected from dogs that had a serum Spec cPL concentration ≥ 400 µg/L 
(considered diagnostic for pancreatitis) and those with a serum cPLI concentration 
within the reference interval of the assay (≤ 200 µg/L). Additional data collected 
included the signalment information of breed, age, and gender. Cases were excluded if 
the breed, age, and gender were not reported as well as the submission form being 
marked as “mixed breed”. Patients with a serum Spec cPL concentration of 201 – 399 
µg/L were also excluded as these represent results within the grey zone of the assay. 
Finally, breeds with less than 15 individuals represented were excluded. This data was 
collected and put into spreadsheet form for statistical analysis. 
 All data were analyzed for normality using a Kolmogorov-Smirnov, D’Agostino 
and Pearson, and a Shapiro-Wilk test. A Mann-Whitney test was used to compare ages 
between the dogs with serum Spec cPL concentrations ≥ 400 µg/L to those with a serum 
Spec cPL within the reference interval. A two-sample test of proportion was used to 
compare proportions based on their gender. 
A χ2 or Fisher’s Exact test was used to compare the proportion of dogs (within 
each individual breed) with increased Spec cPL concentrations compared to the 
proportion of dogs with increased Spec cPL concentrations within the total study 
population (excluding the breed of interest). For each test, odds ratios and their 
respective 95% confidence interval were also calculated. Due to the large number of 
breeds being evaluated, P values were adjusted for multiple testings using the Benjamini 
and Hochberg’s False Discovery Rate test.123 
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In breeds where the odds ratio was found to be greater than one, a logistic 
regression model was developed and fitted to adjust for differences found in age and sex 
that may influence the results. Individual models were tested for Goodness-of-fit with a 
Hosmer-Lemeshow χ2 test. Each model was also tested for multicolinearity, 
overdispersion (ψ), and interaction between variables. All data were analyzed with two 
commercially available software packages.b,c 
Additionally, breeds with statistically significant odds ratios for not having an 
increased Spec cPL concentration compared to the breed population as a whole were 
also recorded and their 95% confidence intervals were calculated.   
 
Results  
 In total, 16,404 dogs were identified and fulfilled the study criteria. This 
population of dogs was represented by 96 individual breeds.  Within this population, 
3,482 (21.2%) had a serum Spec cPL concentration ≥ 400 µg/L.  Dogs with a serum 
Spec cPL concentrations ≥ 400 µg/L were significantly older (median age: 9 years; 
interquartile range: 6-12 years) than dogs with Spec cPL concentrations within the 
reference interval (median: 6 years; interquartile range: 3-9 years; p <0.0001)(Figure 1). 




              
 
 
Figure 1:  Comparison between ages of dogs stratified by Spec cPL concentration. The 
median age of the dogs with a Spec cPL ≤ 200 µg/L was 6 years (interquartile range: 6-
12 years) versus 9 years (IQR: 3-9 years) of age in dogs with a Spec cPL ≥ 400 µg/L. 
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There were no differences in the proportion of males (50.7%) vs. females (49.3%) in the 
dogs with a serum Spec cPL concentration within the reference interval (= 0.1216).  
However, there were significantly more females (53.4%) than males (46.6%) in the dogs 
with a Spec cPL concentration µg/L (< 0.0001) 
Models were constructed to adjust for the effects of age and gender. After model 
adjustment using logistic regression, 13 breeds were identified as having an increased 
odds ratio for having an increased serum Spec cPL concentration. The top five breeds 
with an increased serum cPLI concentration ≥ 400 µg/L were Miniature Pinschers 
(101/208; 48.6%; OR: 3.64), Boxers (236/669; 35.3%; OR: 3.49), Keeshonds (29/52; 
55.8%; OR: 3.24), Pomeranians (106/249; 42.6%; OR: 2.53), and Eskimos (28/61; 
45.9%; OR: 2.02). Other dog breeds with increased odds ratios included Fox Terriers, 
Shetland Sheepdogs, Cocker Spaniels, Dachshunds, Yorkshire Terriers, Rottweilers, 
Standard Schnauzers and Miniature Schnauzers. All P values remained significant after 
model adjustments for multiple testing with the exception of the Standard Schnauzer. 
The complete data set is summarized in Table 1. Additionally, 15 breeds were identified 
as having significant odds ratios for not having an increased Spec cPL proportion 
compared with the rest of the population (Table 2). 
 
Discussion 
This is the first paper to evaluate the association between breed and an increased 














P value Breed N 
GOF P 
value Ψ 
4.71 3.24 1.82 – 5.76 0.000 Keeshond 52 0.980 1.000 
3.58 3.64 2.72 – 4.88 0.000 Miniature Pinscher 208 0.951 1.000 
3.17 2.02 1.19 – 3.44 0.009 Eskimo 61 0.974 0.997 
2.81 2.53 1.94 – 3.31 0.000 Pomeranian 249 0.818 1.001 
2.21 2.07 1.28 – 3.35 0.003 Fox Terrier 78 0.969 1.000 
2.10 3.49 2.93 – 4.17 0.000 Boxer 669 0.749 0.997 
1.83 1.37 1.05 – 1.79 0.022 Shetland Sheepdog 275 0.942 1.000 
1.81 1.37 1.09 – 1.72 0.006 Cocker Spaniel 385 0.253 1.000 
1.58 1.40 1.15 – 1.72 0.001 Dachshund 533 0.956 1.000 
1.56 1.63 1.41 – 1.90 0.000 Yorkshire Terrier 1001 0.542 1.000 
1.55 1.21 0.90 – 1.63 0.208 Standard Schnauzer 232 0.974 1.000 
1.50 1.80 1.37 – 2.36 0.000 Rottweiler 286 0.810 1.000 










Table 1: Breeds with a significant odds ratio for having an increased Spec cPL 
concentration ≥400 µg/L.  Note that the OR for Standard Schnauzers did not reach 
statistical significance after the differences in age and sex were taken into account. GOF 






Odds Ratio P  value Breed N 
0.05 0.0000 Mastiff 74 
0.07 0.0038 Saint Bernard 51 
0.14 0.0073 Akita 54 
0.21 0.0000 German Shepherd 1592 
0.22 0.0072 French Bulldog 70 
0.38 0.0007 Great Dane 171 
0.42 0.0007 Greyhound 223 
0.44 0.0059 Doberman Pinscher 159 
0.48 0.0346 Bulldog (Inc. English Bulldog) 114 
0.49 0.0120 Weimaraner 162 
0.50 0.0066 Siberian Husky 200 
0.61 0.0131 Beagle 288 
0.69 0.0159 Shih Tzu 455 
0.70 0.0036 Golden Retriever 689 




Table 2: Odds ratios and P values for dog breeds with decreased odds for an increased 




submitted for testing by their veterinarian. As these are clinical patients it is likely that 
the majority of these samples were submitted for clinical suspicion of pancreatitis 
although this cannot be verified.  It is interesting to note that the percentage of “positive” 
patients within this population (21.2%) being tested was high. This could be due to 
increased recognition and acumen of veterinarians of the disease process, high 
prevalence of the disease or may reflect the increased sensitivity of this assay. False 
positive test results are another potential reason for the high percentage of positive 
patients, however recent studies evaluating the Spec cPL found the specificity to be 
between 86 and 97.5%.58,79,80,95-97 While histopathology is considered the gold standard 
for pancreatitis diagnosis, this has recently been questioned as to whether this should be 
the diagnostic standard for clinically significant disease.57,61,97,112 A recent study 
demonstrated that focal areas of pancreatitis may be easily missed on biopsy and many 
dogs that had been euthanized for other reasons actually had histopathological evidence 
of pancreatitis.61  Indeed, anecdotally there are many patients with abnormal serum Spec 
cPL concentrations that do not have any clinical signs of pancreatitis.80 In this study, we 
chose to use the most sensitive and specific test that could be performed in a large 
population of dogs.   
Further studies looking at increased serum Spec cPL in large populations of 
healthy dogs would be interesting to compare the prevalence of pancreatitis as well as 
the breed association found in this study. 
The findings of this study support earlier studies that dogs with evidence of 
pancreatitis tend to be older in age.8 We have also identified a higher proportion of 
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female dogs having an increased prevalence compared to male dogs, which was similar 
to a recent study.57 This study did not evaluate the effect of neutering. Due to these 
signalment influences found in this population, the authors used this data to construct 
models that take these effects into consideration when evaluating whether a certain breed 
had an increased prevalence. This study identified an interesting group of dogs with a 
breed predilection for an increased Spec cPL concentration.  
Three of the top five breeds were Keeshonds, Eskimos, and Pomeranians, which 
are closely related. They appear to have all descended from a historic group of dogs 
known as German Spitzs.d This may indicate a genetic etiology in these breeds and 
further investigation of this group of breeds is warranted. Other identified breeds were 
breeds that have been reported previously or anecdotally to be at an increased 
risk.8,55,59,60 Surprisingly, the Miniature Schnauzer, typically considered the prototype 
breed for pancreatitis, did not have the highest prevalence. However, the data on the 
Miniature Schnauzer may be influenced by bias and a resultant increased rate of testing 
by veterinarians due to clinical experience and anectodal reports. Miniature Schnauzers 
with clinical signs of pancreatitis and increased Spec cPL have been found to often be 
homozygous for several variants of the SPINK1 gene in an earlier study.124 A later study 
disputed this finding but this study did not use consistent criteria for diagnosis and also 
did not test the control group for the disease and the intron exon boundary variant was 
not evaluated.125,126 
Several dog breeds were identified with a lower risk for having an increased Spec 
cPL concentration. Most of these breeds were larger breeds and none were breeds that 
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have been previously identified or suggested as being predisposed.  Models were not 
constructed for these breeds as they were not the primary aim of this study but were 
included for clinical interest.   
There are several important shortcomings of this study. These include not 
identifying the reason for clinical testing of the dogs.  Additionally, although an 
excellent assay, the Spec cPL assay does not have a 100% sensitivity and 
specificity.80,96,97 This particular study is also unable to separate those dogs that may 
have acute and suppurative inflammation from those with chronic lymphocytic and 
fibrotic disease as these conditions can only be differentiated by histopathology. As there 
is no way to clinically differentiate the two conditions, the authors acknowledge that 
there may be different breed predispositions between the two conditions. Finally, many 
clinical conditions can mimic the clinical signs of pancreatitis and pancreatitis can be 
secondary to another primary disease process, thus imaging would have been ideal to 
rule out other disease processes. 
Due to the large number of dogs evaluated in this study there are likely some 
errors in the data, such as mixed breed dogs being mislabeled as a particular breed.  
Within a database of this size there also likely exist multiple human transcription errors. 
Additionally, due to the inherent properties of the database and the size of the 
population, cases that were resubmitted for follow-up testing were unable to be 
completely removed from the population. However, care was taken to remove duplicates 
and minimize transcription errors whenever noted. By evaluating a very large number of 
cases, it was hoped that these errors are negligible in their overall effects. 
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In conclusion, this study evaluated a large population of dogs for a breed 
predisposition for an increased serum Spec cPL concentration.  Being female and of 
older age was found to be associated with this laboratory finding.  Additionally, this 
study supports earlier findings that certain breeds may be predisposed to an increased 
Spec cPL concentration and thus possibly pancreatitis. This study also identified a 
closely related group of dogs, Pomeranians, Eskimos, and Keeshonds with a 
predisposition for an increased serum Spec cPL concentration. Further studies looking at 
genetic mechanisms in these dogs are warranted. Furthermore, comparing the breed 
associations found in this study to those in a large general population of healthy dogs 
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INVESTIGATION OF THE VARIANTS OF THE SPINK1 GENE AND THEIR 
ASSOCIATION WITH PANCREATITIS IN MINIATURE SCHNAUZERS1 
 
Introduction 
 The human serine protease inhibitor, Kazal type 1 gene (SPINK1) encodes for a 
protein with a molecular mass of 6.5 kD. This protein, pancreatic secretory trypsin 
inhibitor (PSTI), is produced, stored, and secreted by pancreatic acinar cells.127 The gene 
is approximately 7.5 kb long, has 4 exons, and is located on chromosome 5.128 In 
humans, the product of the SPINK1 gene has been hypothesized to act as an important 
safety mechanisms that protects the pancreas from degradation by premature intra-
pancreatic trypsinogen activation.129 
 Hereditary pancreatitis in humans is a well-known condition that, in a subgroup 
of patients, has been associated with mutations of the SPINK1 gene.43,44,120 Witt et al. 
hypothesized that mutations of the SPINK1 gene may lead to an alteration of protein 
function, which may lead to pancreatic autodigestion and subsequent pancreatitis.44  
 There is evidence to suggest that Miniature Schnauzers have a hereditary 
predisposition towards the development of pancreatitis. A recent retrospective study 
showed that the odds ratio for Miniature Schnauzers to develop pancreatitis was 4.1 
(95%CI: 1.9 – 9.2, p <0.001) when compared to case based controls.60 Additionally, a 
query of the Veterinary Medical Database from 1995 – 2003 showed that the prevalence 
                                                 
1 Reprinted with permission from “Identification of variants of the SPINK1 gene and their association with pancreatitis 
in Miniature Schnauzers” by Bishop MA, Xenoulis MD, Suchodolski JS, Steiner JM. American Journal of Veterinary 
Research, 71, 527-533, Copyright 2010 by Diane A. Fagen, AJVR 
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of a diagnosis of pancreatitis in this breed was 4.4% compared to a prevalence of this 
diagnosis in the general population of 0.7%.a Previous studies have shown that the high 
prevalence of pancreatitis observed in this breed is not associated with any mutations of 
the cationic or anionic trypsinogen genes.b,75 
 Therefore, it was hypothesized that mutations of the SPINK1 gene may be the 
cause of pancreatitis in Miniature Schnauzers. The aim of this study was to sequence and 
evaluate the SPINK1 gene for variants or risk alleles in Miniature Schnauzers with and 
without pancreatitis, and if such variants were identified, to determine if they are 
associated with pancreatitis. 
 
Materials and methods 
 Whole blood and serum samples were collected from healthy Miniature 
Schnauzers, Miniature Schnauzers with pancreatitis, and healthy dogs of other breeds to 
serve as controls.  
 The following criteria were used to define the diagnosis of pancreatitis: clinical 
signs compatible with a diagnosis of pancreatitis (such as vomiting, anorexia, and/or 
abdominal pain), an increased serum canine pancreatic lipase immunoreactivity 
concentration (cPLI ≥200 µg/L) or an increased serum specific canine pancreatic lipase 
(Spec cPL ≥ 400 µg/L) concentration. Dogs with increased serum cPLI or Spec cPL 
concentrations were recruited from a search of the Gastrointestinal Laboratory database 
at Texas A&M University. Each dog’s veterinarian was contacted and asked to fill out a 
questionnaire regarding the clinical signs and overall health of the affected dog. Also, 
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the veterinarian was asked about the date of birth, gender, sexual status, body weight, 
current diet, current medications, and medical history of the dog. If the dogs met the 
previously mentioned criteria, veterinarians were asked to contact the owner for 
permission to enroll the dog. If permission was granted by the owner, signed informed 
consent (protocol reviewed and approved by the Texas A&M University’s Animal Care 
and Use Committee) was obtained and the veterinarian collected whole blood samples 
into tubes containing EDTA and serum. Owners were instructed not to feed their dog for 
at least 12 hours prior to the scheduled blood collection.  
 Samples from healthy Miniature Schnauzers were obtained as part of a separate 
study.91 These dogs were voluntarily enrolled by breeders located throughout the United 
States and samples were collected using the same collection protocol described above. 
Additionally, the owners were questioned and the dogs’ pedigrees were examined to 
ensure they were not related for at least two generations. In order to be considered 
healthy, dogs had to have the absence of any clinical sign of any disease for 3 months 
prior to blood collection and a normal serum cPLI or Spec cPL concentration. Additional 
exclusion criteria included the absence of any prior history of pancreatitis. 
 Samples from healthy dogs of other breeds were obtained from dogs enrolled in 
the study by students and staff at Texas A&M University College of Veterinary 
Medicine and Biomedical Sciences using the same protocol as described above. These 
dogs included: 1Yorkshire Terrier, 2 Border Collies, 2 Beagles, 3 German Shepherd 
Dogs, 1 Coonhound, 3 Lundehunds, 1 Boston Terrier, 1 Alaskan Malamute, 1 Bull 
Mastiff, 3 Chinese Shar Peis, and 5 mixed breed dogs. 
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 All serum samples were analyzed for canine pancreatic lipase immunoreactivity 
concentration using either an in-house ELISA (cPLI) as previously described or a 
commercially available assay (Spec cPL).89 Previous studies have shown that pancreatic 
lipase is specific for the pancreatic acinar cells and the measurement in serum is 
sensitive for the diagnosis of pancreatitis.c,92,130,131  
 DNA was extracted from whole blood samples using a commercially available 
kit according to the manufacturer’s instructions.d 
 
Primer design, PCR, and sequencing 
 The SPINK1 gene in dogs encodes for a protein that is 80 amino acids in length 
and is located on chromosome 2. The gene consists of 4 exons and 3 introns, and has a 
total exon length of 363 base pairs (bp). Exons 1, 2, 3, and 4 consist of 98 bp, 35 bp, 107 
bp, and 123 bp, respectively. The nucleotide sequence of the SPINK1 gene in dogs is 
publicly available (GenBank: XM_845464). This sequence was used to design primers 
to amplify all 4 exons and their respective intron boundaries. Primers were designed 
using a commercially available software programe (Table 3). 
 PCR was performed and optimized for each of the 4 exons. Briefly, for the first 3 
exons, the 25 µl reaction mixture contained approximately 50 ng of genomic DNA, 10X 
Buffer (15 mM Tris HCl, 50 mM KCl (pH 8.0)), 2.5 mM MgCl2, 10 µM of each dNTP, 
0.4 µM of each sense and antisense primer, and 2 units of polymerase.f The conditions 








Exon Primer sequence Product size (bp)
1 F 5' TTCCAGGCCTGCACTGTTTCTTTC 3' 413 
 R 5' CCTGAGTCAAAGGCAGATGCTCAA 3'  
2 F 5' ATGTCTCTGCCTCTCTCTGTGTCT 3' 276 
 R 5' ACAGCTTCACTGTGTGTTGAGTGG 3'  
3 F 5' TACCACTCCCTTTGTCACAGCCTT 3' 343 
 R 5' TGGTTTATTGATTGGAACTTAGAGGGA 3'  
4 F 5' TTTCTCCTATGGTCAATTT 3' 251 












Table 3: Primers for the amplification of canine SPINK1. Key:  F = forward primer, R = 




MgCl2 (3.5 mM). PCR cycling was performed using a commercially available 
thermocyclerg according to the cycling conditions shown in Table 4. 
 Aliquots of the PCR products were electrophoresed on 1% agarose gels at 100 V. 
Gels were stainedh and exposed to UV light for visualization of purity and to ensure the 
correct size of the amplicons. For the initial study, PCR amplicons were ligated into a 
vectori and Escherichia coli organismsj were transformed with the ligants. Plasmids were 
extracted per manufacturer’s instructions using a commercially available plasmid 
purification kit.k The purified amplicon was then sequenced in both directions using the 
ABI BigDye Terminator Sequencing Mix.l The products were analyzed and separated on 
an ABI PRISM 337 DNA Sequencer.m For the association study, PCR products were 
sequenced directly using the same materials and protocols as above.  
 Initially, all four exons and their intron boundaries were amplified from genomic 
DNA in 22 dogs, which included 8 healthy Miniature Schnauzers, 6 Miniature 
Schnauzers with pancreatitis, and 8 healthy dogs of other breeds. Sequences were 
compared to each other and to the published sequences using a commercially available 
software package.n 
 DNA from 65 additional dogs was sequenced in the two regions of the SPINK1 
gene found to carry the three variants identified in the initial study. These additional 
dogs included 17 healthy Miniature Schnauzers (for a total of 25 healthy Miniature 
Schnauzers), 33 Miniature Schnauzers with pancreatitis (for a total of 39 Miniature  
Schnauzers with pancreatitis), and 15 healthy dogs of other breeds (for a total of 23 




















Table 4: PCR cycling conditions for amplification of each exon.124  
 
 Exons 1 & 2 Exon 3 Exon 4 
Step 1 94˚C for 4:00 94˚C for 5:00 - 
Step 2 94˚C for 0:15 94˚C for 0:30 94˚C for 0:30 
Step 3 67˚C for 0:30 67˚C for 0:30 56˚C for 0:30 
Step 4 72˚C for 0:45 72˚C for 1:00 72˚C for 0:30 
Step 5 repeat 34X from step 2 repeat 34X from step 2 repeat 34X from step 2 
Step 6 72˚C for 1:00 72˚C for 2:00 - 
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interest in the SPINK1 gene. The sequences were compared among dogs and with the 
published sequence. 
  The proportions of Miniature Schnauzers with pancreatitis and variants of the 
SPINK1 gene were compared with the number of healthy Miniature Schnauzers with 
variants using a Fisher’s exact test and the odds ratios (OR) and their 95% confidence 
intervals (CI) were calculated. The ages of the two groups of Miniature Schnauzers were 
compared using a Mann Whitney test and an unpaired t test. All data were tested for 




  The sequencing results of the initial 22 dogs revealed 3 different variants. In 
exon 2, two missense mutations were identified. The first was a C to A substitution at 
nucleotide 5, which causes an amino acid substitution for residue 20 (Asn  Lys, 
N20K). The second missense mutation is caused by an A to C substitution at nucleotide 
19, which causes an amino acid substitution at residue 25 (Asn  Thr, N25T). The third 
variant is located on intron 3. This variant is a poly-T insertion and duplication mutation, 
26 nucleotides from the end of exon 3 (IVS3+26-27ins(T)30-39,15_61dup11). All three 
variants were always found together in both healthy Miniature Schnauzers and those 




  In the larger association screening study, the 2 exonic variants were found to 
always appear together in all three dog groups. The intronic variant was only found in 
the two Miniature Schnauzer groups, where the three variants were found in almost 
complete linkage disequilibrium with each other. Interestingly, one healthy Miniature 
Schnauzer was heterozygous for the two exonic variants and did not have the intronic 
variant.  
  Overall, the 3 variants were significantly associated with pancreatitis in 
Miniature Schnauzers. Miniature Schnauzers with pancreatitis were 9.5 times (95%CI: 
1.0 – 87.0; P = 0.0300) as likely to have at least one copy of each of the three variant 
alleles as healthy Miniature Schnauzers. Additionally, pancreatitis in Miniature 
Schnauzers was significantly associated with being homozygous for all three variants 
compared to healthy Miniature Schnauzers. When comparing the proportion of dogs that 
were homozygous for these variants versus the proportion of dogs with wild type alleles, 
the odds ratio was 13.9 (95%CI: 1.4 – 135.6; P = 0.0143). When comparing the number 
of dogs that were homozygous for the 3 variants versus the proportion of dogs that were 
heterozygous or wild type, the odds ratio was 3.4 (95%CI: 1.1 – 9.0; P = 0.0403). 
However, heterozygosity for all 3 variants was not significantly associated with 
pancreatitis in Miniature Schnauzers (P = 0.6046) compared to healthy controls. Finally, 
healthy Miniature Schnauzers were significantly more likely to harbor the exonic 
variants compared to the healthy control group of other breeds (OR: 9.1, 95%CI: 2.4 – 
34.3; P = 0.0011). 
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  There was a statically significant difference in the median age of Miniature 
Schnauzers with pancreatitis versus the healthy Miniature Schnauzer group (P = 0.0009). 
For that reason,  a second control group was generated which included only dogs > 5 
years of age, which have been shown to be at increased risk for pancreatitis.8 After 
exclusion of the younger dogs, a total of 11 healthy Miniature Schnauzers remained in 
the control group. An unpaired t test found that the there was no significant difference in 
the mean ages of the two groups after excluding the dogs younger than 5 years of age (P 
= 0.6606).  Table 5 illustrates the differences in ages and sex among groups. 
  Upon re-analysis of the data with the control dogs of > 5 years of age, it was 
found that Miniature Schnauzers with pancreatitis were 21.7 times (95%CI: 2.1 – 224.4; 
P = 0.0063) as likely to have a least one copy of each of the three variant alleles as 
healthy Miniature Schnauzers. Additionally, pancreatitis in Miniature Schnauzers was 
significantly associated with being homozygous for all three variants compared to 
healthy Miniature Schnauzers. When comparing the proportions of dogs that were 
homozygous for these variants versus the proportion of dogs with wild type alleles, the 
odds ratio was 25 (95%CI: 2.2 – 284.8; P = 0.0067). When comparing the proportion of 
dogs that were homozygous for the 3 variants versus the proportion of dogs that were 
heterozygous or wild type, the results of the Fisher’s exact test was no longer significant 
(P = 0.1658). As before, heterozygosity for all 3 variants was not significantly associated 
with pancreatitis in Miniature Schnauzers (P = 0.1345) compared to the new healthy 










Group n Sex (M:F:UNK) Mean age (yrs) (SD) 
MS w/pancreatitis 39 16:15:8 8.6 (3.4) 
Healthy MS 25 9:15:1 5.3 (3.1) 














Table 5: Age and sex distribution. Key: MS = Miniature Schnauzer, n = total number of 




the preliminary screening and the larger association study, which contains all four 
groups of dogs. 
 
Discussion 
  Pancreatitis has been found to be the most common disease affecting the 
exocrine pancreas in the dog.17 Although acute pancreatitis has been traditionally 
believed to be more common in dogs, recent studies would suggest that, in contrast to 
previous suspicion, chronic pancreatitis may be more common in dogs than acute 
pancreatitis.17 Little is known about whether chronic pancreatitis is caused by recurrent 
bouts of acute pancreatitis or if this condition represents a separate syndrome.  Some 
factors that can serve as potential risk factors for the development of pancreatitis in dogs 
include obesity, trauma, high fat diets, pharmaceuticals, endocrinopathies, and 
hypertriglyceridemia.17 However, most cases of pancreatitis in the dog are considered 
idiopathic as an etiology is rarely definitively identified.61 Because of the breed 
prevalence of pancreatitis in dogs, genetics are proposed to play an important role in the 
development of pancreatitis in some breeds, such as the Miniature Schnauzer, the 
Yorkshire Terrier, and maybe other breeds.5,8,55 
  As mentioned above, in humans SPINK1 is thought to be one of the pancreas’ 
defensive mechanisms against prematurely activated trypsinogen.129 Mutations of the 
SPINK1 gene have been reported in several studies and are thought to be the cause of 
hereditary pancreatitis in humans.44,119-121 Still some authors maintain that the mutations 














2 Healthy OB 
hm/hm/hm 25 (64.1%) 9 (36.0%) 4 (36.4%) 0 (0%) 
ht/ht/ht 13 (33.3%) 10 (40.0%) 3 (27.3%) 0 (0%) 
hm/hm/wild 0 (0%) 0 (0%) 0 1 (4.3%) 
ht/ht/wild 0 (0%) 1 (4.0%) 0 6 (26.1%) 
wild/wild/wild 1 (2.6%) 5 (20.0%) 4 (36.4%) 16 (69.6%) 
total 39 25 11 23 
variant allele 








Table 6: Findings and frequencies of the combined association study. The first column 
gives the possible combinations of alleles seen in this study for each of the three 
mutations. The order corresponds to the presence of N20K/N25T/IVS3+ variants. For 
example, hm/hm/hm would be a dog that was homozygous for both exon variants (N20K 
and N25T) and the intron variant. Key: hm = homozygous, ht = heterozygous, wild = 
wild type, MS = Miniature Schnauzer, OB = other breeds.124 
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modifiers by lowering the threshold for pancreatitis or increasing the severity of the 
disease caused by other genetic or environmental factors.43,118 One study that would 
support this notion reported that when the most common mutation, N34S, was 
recombinantly expressed, the subsequent protein did not show any alteration in its ability 
to inhibit trypsin.132 However, this mutation is also in linkage with four other intronic 
mutations, one of which may be significant.44 Other mutations of the SPINK1 gene have 
been identified and have been shown to be detrimental to protein function or expression. 
An extensive review of these findings can be found elsewhere.133 Finally, mutations in 
other genes, such as the gene for cationic trypsinogen have been associated with 
pancreatitis in humans and may be related to, or act in conjunction, with SPINK1 
mutations.39,122,134  
  To the authors’ knowledge, this is the first study documenting the presence of 
variants of the SPINK1 gene that are associated with pancreatitis in dogs. In this study, 
the exonic variants, N20K and N25T, were always found together in all dogs, regardless 
of the group. However, the intronic variant could only be identified in Miniature 
Schnauzers and also co-segregated with the exonic variants in this breed with the 
exception of one healthy Miniature Schnauzer. This exception could be due to a random 
crossover event or an accidental miss-mating in the past with a dog of another breed. 
The first exonic variant is present at a highly conserved asparginine residue reported in 
many species (Figure 2). The second asparginine at position 25 appears to be unique to 
the dog. The intronic variant is located on intron 3, 26 nucleotides from the end of exon 






Figure 2: Orthologue comparison of the SPINK1 gene between species and location of 
the two exon variants found. Alignment with ClustalW2 (http:// http://www.ebi.ac.uk; 
EMBL-EBI, Hinxton, UK). Key: * = all residues are identical, % = conserved 
substitution, ; = semi-conserved substitution, N = asparagine, K = lysine, T = 




orthologue, suggesting conservation. In this study, Miniature Schnauzers homozygous 
for the 3 variants were significantly more likely to have pancreatitis. In addition, none of 
the healthy dogs of other breeds had the intronic variant. 
   The variants found in the present study are different than those described in 
The variants found in the present study are different than those described in humans with 
hereditary pancreatitis and SPINK mutations.133 However; an intron-exon boundary 
mutation has been reported in people near the location of the intronic variant found in 
the dogs described here. cDNA analysis of this mutation revealed that exon 3 was 
skipped in the final transcript.135 
  There could be several reasons for healthy Miniature Schnauzers to have a high 
prevalence of the 3 variants. First, even though the dogs were clinically healthy at the 
time of sample collection, the variant may predispose them to development of 
pancreatitis later in life. This speculation is supported by the fact that the healthy 
Miniature Schnauzers were significantly younger than Miniature Schnauzers with 
pancreatitis. In this study, age matched controls chosen from the beginning would have 
been ideal; however, it was exceedingly difficult to find healthy older Miniature 
Schnauzers that fulfilled our criteria for inclusion and we felt it was important to a large 
number of dogs. The difficulties were due to the fact that the majority of the older 
Miniature Schnauzers had clinical signs of chronic diseases such as diabetes mellitus and 
urolithiasis, for which Miniature Schnauzers are also predisposed.136,137  However, upon 
exclusion of dogs younger than 5 years of age, it was found, despite having a smaller 
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population of dogs to analyze, that being homozygous for the intron variant was still 
significantly associated with pancreatitis, in fact, even more so. 
  Secondly, mild or subclinical pancreatitis may have easily been missed by the 
owner as mild pancreatitis may be manifested as occasional vomiting or other 
nonspecific clinical signs. Also, a prior episode of pancreatitis may have been 
misdiagnosed as another condition. It is also possible that the gene is highly prevalent, 
but has a low penetrance and it may be necessary for other genes or other environmental 
factors to be present in order for pancreatitis to develop. Additionally, Miniature 
Schnauzers are known to have a highly prevalent syndrome of primary 
hypertriglyceridemia, which itself could be the cause of pancreatitis or a necessary co-
factor.91 The presence of hypertriglyceridemia was not evaluated in this study as it 
would have been difficult to classify the dogs as having hypertriglyceridemia prior to the 
onset of pancreatitis or if the hyperlipidemia was secondary to pancreatic inflammation.8 
Further studies are in progress to investigate the role of hyperlipidemia in the 
development of pancreatitis in the Miniature Schnauzer. Finally, although the cPLI has 
been shown to be the most sensitive (64–82%) serum marker for pancreatitis and is 
believed to be very specific, it is not possible to exclude mild subclinical pancreatitis in 
some of the healthy dogs evaluated.c,o,79,92,98 Histopathological evaluation of the 
pancreas is considered to be the gold standard for the diagnosis of pancreatitis in the 
dog,  but it was not considered feasible. Biopsy of the pancreas is an invasive, expensive 
procedure that is not routinely performed in dogs suspected of pancreatitis. While some 
dogs may have been missed with the measurement of the cPLI/Spec cPL, we feel that 
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the presence of an elevated serum cPLI/Spec cPL concentration plus clinical signs 
compatible with pancreatitis is the most feasible and economical method for phenotype 
assignment in such a large group of dogs that live throughout the United States.  
  In this study, other dog breeds were found to only carry the exonic variants and 
at a lower frequency than Miniature Schnauzers, although many breeds were not studied. 
It could be that the exonic variants are SNPs that have been passed on through 
generations and perhaps the intronic variant represents the etiologic mutation in 
Miniature Schnauzers with chronic pancreatitis.  
  One problem we encountered in this study is the fact that Miniature Schnauzers 
with pancreatitis were significantly older than healthy Miniature Schnauzers. 
Pancreatitis has been shown to develop more commonly in older dogs, and this might 
have accounted for the discrepancy of the prevalence of pancreatitis in the two 
populations of Miniature Schnauzers (healthy vs. sick). However, to more accurately 
compare the true frequency of the variants, as previously mentioned, healthy Miniature 
Schnauzers under 5 years of age were excluded and data was re-evaluated, which 
confirmed the original findings.  
  In addition, population stratification could be another cause of the higher 
variant allele frequency seen in the affected group of Miniature Schnauzers, as a 
relationship among those Miniature Schnauzers could not be conclusively excluded. 
However, sick Miniature Schnauzers enrolled in this study came from many different 
locations within the United States, and we feel that this helped to minimize the 
possibility of selection of a population that were more inbred than the general Miniature 
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Schnauzer population. Finally, only few other dog breeds were studied, and thus the 
variants identified here might be present in breeds that were not included in the present 
study. 
  Further studies are needed to further evaluate the pathogenetic impact of the 3 
variants identified here. Such studies would include the evaluation of the prevalence of 
the 3 variants in the general population of healthy dogs, dogs with pancreatitis, as well as 
in distinct groups such as other breeds with a suspected hereditary predisposition, 
hypertriglyceridemic dogs, and dogs being treated with drugs associated with 
pancreatitis.67 Additionally, studies focusing on possible effects of these mutations on 
the structure and function of SPINK1, mode of inheritance, and penetrance studies are 
warranted. Finally, a genome-wide search for other genes that may be contributing to 
pancreatitis in this breed, as well as a follow-up of the healthy Miniature Schnauzers 
with variants in order to see if they will develop pancreatitis in the future, are needed and 
underway. 
  In conclusion, we have reported 3 closely associated variants (2 exonic and 1 
intronic) of the SPINK1 gene in both healthy Miniature Schnauzers and Miniature 
Schnauzers with pancreatitis. These variants were significantly associated with 
pancreatitis in this study. The exonic variants were also found in healthy dogs of other 
breeds, but at a lower frequency than in healthy Miniature Schnauzers. We conclude that 
defects of the SPINK1 gene likely play a role in pancreatitis in the Miniature Schnauzer. 
However, we also hypothesize that other environmental or genetic factors may also be 
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Miniature Schnauzers have long been suspected to be predisposed to the 
development of pancreatitis. Indeed a recent epidemiological study investigating risk 
factors for pancreatitis identified the Miniature Schnauzer as having an increased odds 
ratio.60 Additionally, a previous candidate gene study identified Miniature Schnauzers, 
with a phenotype consisting of clinical signs and an increased Spec cPL concentration, 
that were associated with being homozygous for two exon and one intron/exon boundary 
variants in the serum protease inhibitor, Kazal type 1 (SPINK1) gene.124 However that 
study suggested that the SPINK1 gene may not be the only gene involved in the etiology 
of pancreatitis in this breed and that the condition may be polygenic or that it might be 
multifactorial and that some environmental factor may also be playing a role.  Previous 
evaluation of the cationic trypsinogen, anionic trypsinogen, and lipoprotein lipase genes 
did not reveal any mutations in Miniature Schnauzers with pancreatitis.17,75 In order to 
further investigate other candidate genes, a comprehensive genome-wide scan would be 
warranted. 
Genome wide mapping using single nucleotide polymorphisms (SNPs) is now a 
common tool for identifying chromosomal regions and candidate genes of interest.138-142 
After the publication of the canine genome, a high density SNP map has been 
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constructed that identifies approximately 2.5 million SNPs with a density average of 1 
SNP per kilobase throughout the entire canine genome.138 Subsequently a SNP array 
using a high through-put platform was developed and validated. The original SNP array 
utilized a set of 26,578 SNPs using 10 different dog breeds.138,141 The commercially 
available chip was expanded to include 49,663 SNPs and is known as the v2 platinum 
array. With this methodology, PCR primers that code for the different SNP variations are 
bound to a chip and tagged with a reporter molecule. DNA from the patient is washed 
over the chip and hybridizes with the primers. Hybridization is communicated by 
reporter molecules and subsequently each patient is genotyped for each individual 
SNP.141 DNA is collected from dogs with the disease of interest and normal healthy 
controls and their genotypes are compared. Statistical associations between disease and 
areas of the genome may point to areas that contain the gene(s) of interest. Areas of 
interest can be further investigated by gene sequencing or more refined SNP evaluation. 
The aim of this study was to identify a region of interest or candidate genes that 
are associated with the phenotype of clinical signs of pancreatitis and increased Spec 
cPL concentrations in Miniature Schnauzers. A secondary aim of the study is to evaluate 
whether the previously identified variants in the SPINK1 gene are identified in a genome 
wide scan.  
 
Materials and methods  
Whole blood and serum samples were collected from Miniature Schnauzers with 
a history of clinical signs compatible with pancreatitis (i.e., vomiting, abdominal pain, 
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and diarrhea) and an increased serum Spec cPL concentration as well as from healthy 
control dogs with an absence of clinical signs of disease and a serum Spec concentration 
within the reference interval. The dogs were client-owned animals that were solicited by 
calling Miniature Schnauzer breeders and searching the database at the Gastrointestinal 
Laboratory at Texas A&M University for samples from dogs submitted for the 
measurement of serum cPLI or Spec cPL concentration. History and clinical signs were 
obtained via mailed questionnaires or phone calls to referring veterinarians or breeders. 
Pancreatitis was diagnosed on the basis of the following criteria: clinical signs 
compatible with a diagnosis of pancreatitis (i.e., vomiting, anorexia, abdominal pain, 
diarrhea, or a combination of these) and an increase in serum cPLI concentration as 
measured by the original in-house ELISA ≥ 200 µg/L or as measured by Spec cPL ≥ 400 
µg/L. In order to be considered healthy, Miniature Schnauzers had to have no clinical 
signs of any disease for 3 months prior to blood collection, no prior history of 
pancreatitis, and have a serum cPLI concentration within the reference interval. 
 DNA was extracted from whole blood using a commercially available DNA 
purification kit and spectrophotometry was performed for both quantification and to 
ensure high quality samples utilizing the A260/A280 ratio.a,b Only DNA with a A260/A280 
ratio of 1.6 or greater was used for further analysis. DNA was frozen at -20oC until 
enough samples were collected for analysis. DNA was then shipped frozen to the 
Vanderbilt Microarray Shared Resource Laboratory for genotyping using the 
commercially available v2 Platinum Array.c Results were analyzed using a commercially 
available software package.d Association testing was performed via χ2 tests for each 
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SNP and because of the large amount of multiple testing in this study, a Bonferroni 
correction for multiple statistical comparisons was used to determine significance. Alpha 
was set 0.5 for individual tests, but the overall significance was set to a conservative P < 
0.00001 (P < 1.0 x 10-6). Significant SNP’s were located on the canine genome assembly 
CanFam 2.0.e,138 The ages of the dogs belonging to the two groups were compared with 
an unpaired t test as data was found to be parametric. 
 
Results  
 In total, 50 dogs were used for SNP analysis.  There were 39 Miniature 
Schnauzers that fulfilled the inclusion criteria of having an increased serum cPLI 
concentration and clinical signs of pancreatitis. There were a total of 25 Miniature 
Schnauzers that were considered healthy, however this group as a whole was much 
younger (mean ± standard deviation) (5.3 ± 3.1 years) compared to those with clinical 
signs (8.6 ± 3.4 years) (P < 0.001). Due to this discrepancy and in order to age match 
these two groups for analysis, only dogs that were greater than 5 years of age were 
included in the population of healthy dogs. This was based on a previous report that dogs 
over the age of 5 were at increased risk for pancreatitis.8 Therefore, in total 11 healthy 
dogs were analyzed and they had a mean age of 8.1 ± 1.8 years (P = 0.6610).  
SNP analysis only returned one SNP that fulfilled the very conservative P value 
criteria. The location of this SNIP was identified on chromosome 2 at location 
40,905,350 and the returned P value was 2.9 x 10-7. Additionally, although not 
statistically significant per our criteria, there were 13 other SNPs with P values < 0.0001 
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that were also located on chromosome 2. These other SNPs are very close to the 
statistically significant SNP and they encompass the region from positions 40,339,715 to 
43,363,462. These locations were identified on the canine genome assembly on 
chromosome 2. There are 40 known genes which occupy this location and the SPINK1 
gene is located at position 42,112,016 to 42,120,711. The SPINK1 gene is centered in the 
region identified by the SNP array. (Figure 3). Several similar genes that encode for 
SPINK5 and SPINK6 are in the same region. The remaining genes encode for g protein 
receptors and other intracellular functions. There were no other pancreatic specific 
proteins or other obvious candidate genes identified that occupy this region. 
 
Discussion 
The results of this study show an association of the disease phenotype to a small 
region of chromosome 2. This is based on clustering of the SNP results occurring around 
this locus. These results support a previously reported association of the phenotype with 
variants in the SPINK1 gene of Miniature Schnauzers.126 The SPINK1 gene codes for the 
protein, pancreatic secretory trypsin inhibitor (PSTI).128 This is an acute-phase protein 
that is thought to act as one of the fail-safe mechanisms to prevent auto-digestion of the 
pancreas by binding to prematurely activated trypsin within the acinar cell.9,17 In 
humans, a N34S missense mutation of this gene has been associated with idiopathic 
pancreatitis.40,43,44,119,135  Further studies showed an increased prevalence of the variant 
and others as well as a large number of heterozygous individuals within pancreatitis 












Figure 3:  Animation of the SNP’s identified on the canine chromosome 2 that were 
associated with the phenotype of pancreatitis.  The red bar indicates the SPINK1 gene 
and its relative location to other SNPs.  Numbers are the location on the genome where 
SNPs are located.  
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mutation. A recent meta-analysis study found that variants were more closely tied to the 
development of idiopathic and chronic pancreatitis than alcohol usage.21,45 Other variants 
including a splice variant has been identified and currently SPINK1 is considered to be 
the causative mutation in homozygous individuals.36,135 However, in heterozygous 
individuals, SPINK1 is only considered the cause when no other mutations can be 
identified (PRSS1, CFTR, etc.).21,45 
 The data of this study suggest that the region identified on the canine 
chromosome 2 may likely contain the gene(s) of interest in Miniature Schnauzers with 
evidence of pancreatitis. While it is of great interest that the SPINK1 gene is located in 
the region with disease-associated SNIPs, other genes in this region could be causative 
despite not finding any other obvious targets in this location.  Further refined SNP 
mapping using informative SNPs that are not on the genotyping chip may help to narrow 
the region or possibly locate other candidate genes that could be sequenced. 
Alternatively, the SPINK1 gene may be playing a role in a more complex phenotype that 
may require other environmental or metabolic factors to be present (i.e., hyperlipidemia 
or dietary factors).60,76,91,124 Indeed, being a Miniature Schnauzers with a serum 
triglyceride concentration over 900 mg/dl has previously been associated with a 
significantly increased odds ratio for an increased Spec cPL concentration.76 Further 
studies including the construction of a logistic regression model containing information 
on Miniature Schnauzers SPINK1 genotype as well as their fasting triglyceride 
concentrations may help to clarify if such a connection exists. 
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The shortcomings of this project include the smaller population of healthy 
individuals.  However, it was surprisingly difficult to find Miniature Schnauzers that 
fulfilled our requirements to be considered healthy. Indeed, Miniature Schnauzers appear 
to have a predisposition for several chronic conditions as they age.64,137 However, recent 
bottlenecking of the canine population allows for long linkage disequilibrium within 
breeds and short linkage within the population.138,141 This allows for a small number of 
dogs to be used in SNP genotyping studies. In fact, recent studies used only 20 dogs to 
identify a discrete region for a simple recessive trait while a dominant trait such as 
hyperparathyroidism in Keeshonds was genotyped with 70 dogs using SNP analysis.141 
Also, spotting on boxer dogs was identified using SNP analysis with only 36 dogs.142 
Studies as these in dogs and studies in humans have found SNP association to be 
valuable for locating both simple and complex genetic diseases.138,143,144 At this point, it 
appears that pancreatitis in Miniature Schnauzers may be polygenic and as a result, a 
larger number of dogs would be needed. Indeed, had a larger population been available, 
the other SNPs at the chromosome 2 location may have become statistically significant. 
Additionally, the establishment of an exact phenotype is difficult with this 
disease process. The gold standard for diagnosis of pancreatitis is currently considered to 
be pancreatic biopsy although many experts are calling this into question.57,61,97,112 With 
the advent of assays for the measurement of cPLI many clinicians consider the presence 
of an increased serum concentration and clinical signs to be consistent with the diagnosis 
after having ruled out other differential diagnoes.80 Recent studies have demonstrated 
small focal pancreatic lesions in dogs without overt signs of pancreatitis.112 Indeed in 
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this study, some of the “healthy” dogs may have had clinically insignificant pancreatitis 
on histopathology. Additionally, the dogs with the phenotype of pancreatitis in this study 
may have had the acute neutrophilic form of the disease versus the more chronic 
lymphocytic-plasmacytic form. In humans, SPINK1 mutations are associated with 
histopathologic findings of chronic disease.36,40 Ideally, dogs in the study would have 
had a pancreatic biopsy to further classify these two different disease entities. However, 
pancreatic biopsy is invasive, costly, and generally impractical.5,17,65 While the 
phenotype established in this study should identify individuals with pancreatitis, we 
were unable to definitively rule out other disease processes. Also, while pancreatitis can 
be a primary condition, it can also be secondary to many disease conditions such as 
peritonitis or neoplasia.17 
In this study we did utilize both the original ELISA for the measurement of 
serum cPLI concentration as well as the Spec cPL. Ideally the same assay would have 
been used to establish the phenotype for the entire study. However, during a period of 
sample collection for this study, only the original ELISA was available for use, while 
later on the original ELISA was discontinued and replaced with the Spec cPL.80 Both 
assays have been fully evaluated and are considered equivalent.96,97  
In conclusion, this study has identified a region of interest on canine 
chromosome 2 in Miniature Schnauzers with a phenotype of an increased serum cPLI 
concentration and clinical signs compatible with pancreatitis. In the region identified the 
SPINK1 gene is located suggesting this gene to likely play a role in the etiology of 
pancreatitis in the Miniature Schnauzer. Further refined mapping of the region with a 
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larger population of dogs may identify other targets that may play a role in the etiology 
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EVALUATION OF THE CDNA IN MINIATURE SCHNAUZERS WITH VARIANTS 
IN THEIR SPINK1 GENE 
 
Introduction 
Previous studies have identified variants in the SPINK1 gene of Miniature 
Schnauzers with clinical signs of pancreatitis and an increased serum cPLI 
concentration.124 Two of these variants reflect single nucleotide substitutions that would 
change the cDNA of the second exon of the SPINK1 gene (Figure 4). The first missense 
mutation, N20K, changes the sequence from the uncharged polar amino acid asparagine 
to the charged polar amino acid lysine (Figure 5). The second variant, N25T, replaces 
asparagine with threonine (Figure 6). Besides these two variants, another abnormality 
was noted along the intron-exon boundary between intron 3 and exon 4 of the gene. This 
is an insertion and duplication mutation, known as IVS3+26-27ins(T)30-39,15_16dup11. 
This variant inserts a variable poly-t sequence and then reduplicates 11 nucleotides 
upstream from the poly-t insertion and repeats them after the variable strand of thymine 
(Figure 7). It was also noted that these three missense mutations were in linkage in 
Miniature Schnauzers and while some dogs of other breeds did have the exon variants, 
the boundary mutation was unique to the Miniature Schnauzer.124 Additionally, 
Miniature Schnauzers were more likely to be homozygous for all three variants. It was 
hypothesized that this intron exon boundary mutation could be causative for pancreatitis 






























Figure 4:  Sequencing results of the second exon of the SPINK1 gene.  The wild type 
sequence is shown in the bottom graph. The red box indicates the substitution of the 
nucleotide that will change the codon present at that location. Letters correspond to the 


























































Figure 6: Missense mutation with a non-conservative substitution at the second locus on 






















Figure 7:  Sequencing results of the intron/exon boundary between the third intron and 
the third exon of the SPINK1 gene in Miniature Schnauzers with evidence of 
pancreatitis.  The bold red line indicates the boundary between exon and intron with the 
blue arrow pointing upstream toward exon 3 and the green arrow pointing downstream 
toward intron 3. The red box indicates the set of nucleotides that is reduplicated further 






The aim of this study was to further investigate the effects of the intron-exon 
boundary mutation by evaluation of the cDNA of Miniature Schnauzers that are 
homozygous, heterozygous, or wild type for the three SPINK1 variants. 
 
Materials and methods  
 Breeders of pedigreed Miniature Schnauzers were solicited throughout Texas by 
contacting the Miniature Schnauzer breed association. Breeders were telephoned or 
emailed to recruit female, sexually intact Miniature Schnauzers bitches that were ready 
to be retired and adopted to new homes. These dogs had to be clinically healthy on 
physical examination and have unremarkable full bloodwork, including a complete 
blood count, chemistry panel, and a urinalysis. In addition, blood samples were collected 
for genotyping each dog for the three known SPINK1 variants. DNA was extracted and 
isolated from each dog using a commercially available kit.a Each dog’s genotype for the 
three variants was determined using PCR. Briefly, exon 2 and the boundary of the intron 
3 and exon 4 were amplified with SPINK1 specific primers using a PCR as previously 
reported.  For exon 2, the 25 µl reaction mixture contained approximately 50 ng of 
genomic DNA, 10X Buffer (15 mM Tris HCl, 50 mM KCl (pH 8.0)), 2.5 mM MgCl2, 10 
µM of each dNTP, 0.4 µM of each sense and antisense primer, and 2 units of 
polymerase.  For the fourth exon, the MgCl2 concentration was greater at 3.5 mM.  PCR 
cycling conditions were as previously described.124 The PCR product was directly 
sequenced in both directions using the terminator sequencing mix and the products were 
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analyzed and separated on a DNA sequencer to determine the genotype of each dog.b,c 
Dogs that were found to have the variants as well as a single dog that was wild type for 
the variates were subsequently purchased from the breeders and housed at the Texas 
A&M University College of Veterinary Medicine Teaching Hospital.   
 Once each dog was settled into the hospital, an additional examination was 
performed by a veterinarian and another blood sample was taken to evaluate each dog’s 
serum Spec cPL concentration in order to assure pancreatitis was not present at the time 
of surgery.d Each dog was fasted overnight and taken to surgery under general 
anesthesia, which was performed by a board certified veterinary surgeon. Prior to 
surgery each dog was given a morphine epidural and was induced with propofol after 
hydromorphone and glycopyrrolate premedication. Monitoring of anesthesia was 
performed by a board certified anesthesiologist. Crystalloids were administered 
intravenously at a rate 10 ml/kg/hour to maintain perfusion and normotension. The first 
procedure performed was an ovariohysterectomy. Briefly, the ventral abdomen was 
clipped and surgically prepped from the area of the xiphoid to the pubis. A surgical 
incision was made just caudal to the umbilicus extending 4 – 8 cm caudal through the 
skin and subcutaneous tissue to expose the linea alba. The linea alba was grasped with 
forceps and a stab incision into the abdominal cavity was made. This incision was 
extended with Mayo scissors. The reproductive tract was then identified by confirming 
that the uterine horn extends to an ovary cranial and the uterine bifurcation and cervix 
caudally. The suspensory ligament was identified at its attachment to the ovarian 
pedicle. This ligament was stretched and torn to allow exteriorization of the ovary. A 
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hole was made in the broad ligament caudal to the ovarian pedicle and one to two 
Rochester-Carmalt forceps were placed across the ovarian pedicle proximal to the ovary 
and one additional forceps across the proper ligament of the ovary. Using absorbable 
suture, the pedicle was ligated with circumferential and transfixing ligatures following 
forceps removal. After ligation, the ovarian pedicle was transected between the sutures 
and the ovary. The remaining stump was inspected for bleeding and knot security and 
then released back into the abdominal cavity. This process was repeated for the other 
ovary. To ligate the uterus, a figure-eight suture was placed through the uterine body 
near the cervix, then a second circumferential ligature was placed closer to the cervix.  A 
Carmalt forceps were placed proximal to the ligatures and the uterine body was 
transected with a scalpel between the forceps and the ligature. Upon ensuring the uterine 
stump was not hemorrhaging, it was released back into the abdominal cavity.    
 After completing the ovariohysterectomy, the skin, subcutaneous, and linea alba 
incision was extended cranial to the xiphoid as needed to visualize the pancreas. The 
pancreas was identified by cranial retraction of the free portion of the greater omentum 
and grossly evaluated for any pancreatic pathology. A small portion of the distal aspect 
of the right lobe of the pancreas was incised by using individual lobule dissection. To 
perform this procedure, an incision was made in the mesoduodenum and a portion of the 
distal right limb of the pancreas was exteriorized. Using a small pair of Metzenbaum 
scissors, the lobules were gently teased and removed from the body of the pancreas.  
Attempts were made to preserve pancreatic ducts and hemorrhage was controlled by 
using small absorbable sutures as needed. The pancreas was then observed for gross 
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hemorrhage prior to body wall closure. Closure of the linea alba was performed by using 
absorbable suture material in a simple continuous pattern, followed by closure of the 
subcutaneous and intradermal tissues in a similar fashion. The skin incision was then 
covered by a bandage.e After surgery, each dog was recovered in the intensive care unit 
of the Texas A&M University College of Veterinary Medicine’s Teaching Hospital 
under the care of a veterinarian. Each dog was administered IV lactated Ringers solution 
at rate of 120 ml/kg/day and given injectable buprenorphine at 0.01 mg/kg intravenously 
every 8 hours for pain control and then transitioned to oral meloxicam at a dose of 0.1 
mg/kg orally every 24 hours. Blood samples were collected at approximately 12, 36, and 
60 hours after surgery to monitor for possible post-operative pancreatitis. 
 At the time of surgery, the pancreatic biopsy was immediately placed into liquid 
nitrogen. Once completely frozen, the tissue sample was extracted from the liquid 
nitrogen and immediately stored at -80oC. In order to extract mRNA from the pancreas, 
a commercially available purification kit was used in a modified manner.f Each tissue 
sample was retrieved from the freezer, quickly weighed, and while still frozen was 
placed in a vial containing 1 ml of TRIzol per 100 mg of pancreatic tissue.g The sample 
was immediately homogenized using a tissue homogenizer. To extract the mRNA, after 
a 5 minute incubation, 0.2 mLs of chloroform was added to the sample per every 1 ml of 
TRIzol that had been previously added. The sample was incubated for 3 minutes and 
then centrifuged at 12,000 x g for 15 minutes at 4oC. After separation, the upper phase 
was transferred to a clean tube.  This upper phase was then mixed with an equal volume 
of 70% ethanol and transferred to a spin column and centrifuged for 15 seconds at 
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12,000 x g to bind the sample to the spin cartridge.h The sample was then washed twice 
with a commercially available wash bufferi. The final purified mRNA was extracted 
from the column with RNase free water.j  The samples then underwent 
spectrophotometry to evaluate their purity and concentration.k Samples were stored at -
80oC prior to reverse transcriptase polymerase chain reaction (RT-PCR). 
 Primers were constructed to amplify the entire cDNA of the SPINK1 gene.  The 
forward primer was 5’ TGGCCCTGTTGAGCTTATCTGGTA and the reverse primer 
was 5’TCAGGCCCACTAGGCATTGTAGTA.l Using a commercially available RT-
PCR kit, 1 µg of RNA was combined with 11.4 µl of RNAase free water, 10 µl of 5x 
RT-PCR buffer (2.5 mM Mg2+), 400 µM of each dNTP, 0.6 µM of each primer, and 2 µl 
of reverse transcriptasesm. RT-PCR was performed in a thermocycler according to the 
manufacture’s recommendations.n cDNA from each dog was sequenced in the sense and 
anti-sense directions as described previously above. cDNA sequences were compared to 
the known SPINK1 cDNA sequence from the canine genome assembly CanFam 2.0.o,138 
 After surgery each dog was fully recovered and these dogs were adopted out to 




  In total, 15 Miniature Schnauzers were screened for inclusion into the study.  
However only  4 Miniature Schnauzers were able to be obtained and meet full 
requirements for surgery. Each dog was sequenced to determine whether they contained 
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the previously identified exon 2 missense and the intron/exon boundary mutations. One 
dog was wild type for all three variants, two were heterozygous for each of the variants 
and one dog was homozygous for all three variants.   
All four dogs recovered from surgery and were successfully adopted. Spec cPL 
serum concentrations remained within the reference interval at 12, 36, and 60 hours post 
op for all dogs. 
cDNA was successfully isolated from each of the dogs’ pancreatic biopsy using 
the technique described. RT-PCR was also successfully performed on each sample.   The 
subsequent amino acid sequences (as would be coded) were aligned however there were 
no differences noted in the length or any other abnormalities with the exception of the 
exon 2 variants (Figure 8). 
 
Discussion 
 The SPINK1 gene encodes for the protein pancreatic secretory trypsin inhibitor, 
which is thought to act as one of the pancreas fail-safe mechanisms to prevent auto-
digestion.9,16,128 The protein is expressed within the acinar cell of the pancreas and has 
been shown to bind to prematurely activated trypsin, thus preventing or limiting the co-
localization of zymogens with lysosomes.5,9,17  
Homozygosity for the N34S SPINK1 gene mutations in humans is now 
considered causative for idiopathic pancreatitis.21,36,40,45 Heterozygous individuals are 
not considered causative unless no other mutations are identified in other genes known 















Figure 8:   Amino acid sequence of Miniature Schnauzers with SPINK1 variants.  WILD 
= wild type sequence, HETZ = Heterozygous for variants, HOMO = Homozygous for 
the variants.  Letter code for individual amino acids.  X = indicates that the amino acid 




was identified and was found to cause the skipping of exon 3, which is the location of 
the trypsin binding site and transcription expression was decreased to 62% of wild-type 
SPINK1 in heterozygous patients.135    
This paper likely describes the first successful attempt to purify mRNA directly 
from the pancreas of dogs. mRNA extraction from the pancreas has been difficult due to 
extremely high number of proteases and other degradation enzymes present within the 
pancreas.145 cDNA was successfully transcribed in a wild type dog, two heterozygous 
dogs, and a homozygous dog with the SPINK1 variants previously described to be 
associated with the phenotype of clinical signs of pancreatitis and increased Spec cPL 
concentrations.   
A previous study suggested that the intron/exon boundary variant is unique to 
Miniature Schnauzers, however cDNA analysis does not appear to alter the final 
transcript in length and all 4 exons remain in place.124 While the cDNA does not alter the 
transcript, other than the two exon variants, this does not mean that any of the 3 variants 
are not causative. Indeed, many mutations have been found to be coded correctly but in 
vitro experimentation revealed decreased levels of mRNA expression or dysfunction of 
the subsequent protein.21  
Further studies using cell culture where the SPINK1 mutated protein is expressed 
may clarify any effects on protein expression levels. Additionally, further studies 
documenting the mutated protein’s ability to bind trypsin are also warranted. Finally, x-
ray crystallography analysis may demonstrate any changes in protein folding that may 
open or close binding sites necessary for protein function. 
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Even though this study was extremely small (n=4), it confirms previous studies 
that pancreatic biopsy, when collected with caution, is a safe procedure. All dogs 
recovered well from surgery with no clinical signs of pancreatitis and their Spec cPL 
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SUMMARY AND CONCLUSIONS 
  
 The Miniature Schnauzer has long been suspected to have a genetic 
predisposition to pancreatitis, However, few studies have been attempted to prove this 
association.8,59,60,77 The primary roadblock to this success was the absence of a non-
invasive marker for diagnosing the condition. With the advent of cPLI, further study of 
such an association became feasible..80,89,90 
 In humans, severeal genetic mutations have been discovered that are now 
considered to play an important role in the etiology of chronic and idiopathic 
pancreatitis.39,40,45 Previous studies have investigated several candidate genes in 
Miniature Schnauzers (i.e., cationic, anionic, and lipoprotein lipase genes) with no 
success.75 The hypotheses of this study were that 1) Miniature Schnauzers are 
predisposed to the development of pancreatitis based on a phenotype of an increased 
serum cPLI concentration and clinical signs, 2) the SPINK1 gene would harbor potential 
genetic mutations, and 3) using SNP analysis, we would be able to identify gene(s) or 
regions that are associated with the phenotype of pancreatitis. Thus, the objective of this 
study was 1) to prove an association with the clinical condition in the Miniature 
Schnauzer breed, 2) to investigate other possible candidate genes, and 3) to explore the 




 In the first part of this study, a large scale retrospective study was constructed to 
look at the breed prevalence of increased serum Spec cPL concentrations in a  large 
population of clinical samples submitted for analysis. A large sample size was obtained 
and the numbers of dogs within a breed and the percentage of those with an increased 
Spec cPL concentration were compared to the frequency of the population as a whole 
minus the breed of interest. This study was able to identify 13 breeds with a statistically 
significant odds ratio for having an increased Spec cPL concentration. The top dog 
breeds were the Miniature Pinscher (OR: 3.64), the Boxer (OR: 3.49), the Keeshond 
(OR: 3.24), the Pomeranian (OR: 2.53), and the Alaskan Eskimo (OR: 2.02). Miniature 
Schnauzers, although not showing the highest association, were also significantly 
associated (OR: 1.23). While proving the association for Miniature Schnauzers was the 
primary aim of the study, this project was able to identify three closely related dog 
breed, (i.e., Keeshonds, Pomeranians, and Eskimos), which all originally descended 
from Germany.  Further investigation into this group of dogs is warranted. 
 This study was also able confirm early reports that dogs with pancreatitis are 
more likely to be older (median 9 years vs. 6 years). However this is the first report to 
demonstrate a statistically significantly increased prevalence in female dogs (53.4% vs. 
46.6%; P <0.0001). Earlier studies demonstrated that neutering increased the risk, 
however sexual status was not investigated in this study due to the very small number of 
intact animals in this large population of dogs. 
 The second part of the study investigated the candidate gene SPINK1. This gene 
encodes for the pancreatic secretory trypsin inhibitor, which acts to bind prematurely 
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activated trypsin within the acinar cell of the pancreas.5 Earlier studies in humans 
pointed to mutations of this gene being causative for idiopathic chronic pancreatitis.43,44 
Later studies, similar to what was found in this study, demonstrated a high prevalence of 
the variants in the general population.43 However, a recent meta-analysis was able to 
demonstrate that SPINK1 mutations can indeed be causative.45 Currently, homozygosity 
of the most common SPINK1 mutation is considered the etiology of pancreatitis when 
present. Heterozygosity for the same mutation is also considered causative if the 
individual does not have any mutations in the PRSS1, CFTR and other known genes.21 
 In this study, three variants in the SPINK1 gene were identified. Two of the 
variants were located in exon 2 and changed the coding of the three nucleotide codon.  
The other variant that was found, was unique to only Miniature Schnauzers and was 
found at the boundary of exon 3 with intron 3. It was found in the study that all three 
variants were always linked in the Miniature Schnauzers, and those that were 
homozygous for all three variants were 23 times more likely to have the phenotype of 
pancreatitis. The study does open up the question as to why, although at a much lower 
prevalence, the exon variants are common in the general population. These variants may 
be SNP’s that are in linkage with the intron/exon boundary mutation or perhaps being 
only homozygous makes this important. Miniature Schnauzers have also been 
demonstrated to be prone to familiar hyperlipidemia and this may a play a role in the 
phenotype. This study posed the question if other genes may also be involved in the 
etiology of pancreatitis in the Miniature Schnauzer. It also posed the question as to 
whether the variants of the SPINK1 gene lead to an altered final transcript. 
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 The third component of this study was designed to answer questions raised 
during the second part of the study. It was clear that not all Miniature Schnauzers with 
pancreatitis were homozygous for all three variants although there are other known risk 
factors for the development of pancreatitis. The goal of the second part of this study was 
to conduct a genome wide investigation into other possible targets as well as to 
determine if the region of the SPINK1 gene would be identified as a candidate gene were 
the aims of this study. The genome wide scan was able to point at a small region on 
chromosome 2 that was associated with the phenotype established. Interestingly, the 
SPINK1 gene was in this region. While there were many other genes in this area, none 
others have been identified in human studies as being potential candidate genes. This 
finding begs the question as to whether SPINK1 variants alone are the genetic 
component or if there is some other environmental factor (dietary indiscretion) that is 
also needed. However, it is possible that other genes in this area could also be associated 
and more refined SNP mapping using a large population of dogs would be needed to 
further locate genes that may be worth sequencing. 
 The final section of this study was to investigate the missense variants that were 
identified in the second part of this study. In order to achieve this, a protocol was 
developed for the extraction of the mRNA from the pancreas of live patients undergoing 
surgery for other reasons. Indeed, collection mRNA from deceased patients is almost 
impossible due to the large amounts of proteases and digestive enzymes present in the 
pancreas.145 Dogs that were to be sexually altered were obtained from breeders and 
placed in new homes after completion of the study. During their elective surgery, 
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pancreatic biopsies were collected for mRNA extraction. cDNA primers of the SPINK1 
gene were constructed to amplify the entire cDNA of the canine gene. Using RT-PCR, 
cDNA was successfully transcribed and dogs that were homozygous, heterozygous, and 
wild type for the variants were compared. While the exon variants did change the coding 
sequence as was predicted, the intron/exon boundary variant did not alter the final form 
of canine SPINK1 cDNA.  However, mutations can affect protein production in a variety 
of ways with exon skipping or truncation being only one mechanism. The exon variants 
could also affect the structure and function of the subsequent protein or any of the 
variants may alter the expression of the protein in vivo. This study warrants further 
investigation using cell culture to analyze expression and in vitro trypsin binding. 
 In summary, the main conclusions of this study were: 
1) Miniature Schnauzers for which samples have been submitted for pancreatic function 
testing are more likely to be positive for pancreatitis than the population as a whole. 
2) Keeshonds, Pomeranians, and Eskimos are a closely related group of dogs that, based 
on this study, are predisposed to having an increased serum Spec cPL concentration. 
3) Dogs with an increased Spec cPL concentration are more likely to be female and of 
older age than their cohorts. 
4) Miniature Schnauzers have three missense variants located in their SPINK1 gene.  
These variants were always in linkage in this study. 
5) Homozygosity for these three variants in the Miniature Schnauzers is significantly 
associated with clinical signs of pancreatitis and an increased serum cPLI concentration. 
88 
6) The exon variants identified are not unique to Miniature Schnauzers. However, they
occur at a lower prevalence in other breeds than in the Miniature Schnauzers. 
7) The intron/exon boundary variant is unique to Miniature Schnauzers.
8) The region between 40,339,715 to 44,189,359 on canine chromosome 2 is associated
with having clinical signs of pancreatitis and an increased serum Spec cPL 
concentration. The SPINK1 gene is also located in this region. 
9) mRNA can be successfully extracted from the pancreas of live dogs in excellent
quality and usability for downstream application. 
10) The intron/exon variant of the SPINK1 gene does not alter the final cDNA product.
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